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Abstract
The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial:
a randomised controlled trial to determine whether or not
intermittent pneumatic compression reduces the risk of
post-stroke deep vein thrombosis and to estimate its
cost-effectiveness
Martin Dennis,1* Peter Sandercock,1 Catriona Graham2 and
John Forbes3 on behalf of the CLOTS (Clots in Legs Or sTockings after
Stroke) Trials Collaboration†
1Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
2Epidemiology and Statistics Core, Wellcome Trust Clinical Research Facility,
University of Edinburgh, Edinburgh, UK
3Health Research Institute, University of Limerick, Limerick, Ireland
*Corresponding author martin.dennis@ed.ac.uk
†See Appendix 1 for the members of the CLOTS trial collaboration
Background: Venous thromboembolism (VTE) is a common cause of death and morbidity in stroke patients.
There are few data concerning the effectiveness of intermittent pneumatic compression (IPC) in treating
patients with stroke.
Objectives: To establish whether or not the application of IPC to the legs of immobile stroke patients
reduced their risk of deep vein thrombosis (DVT).
Design: Clots in Legs Or sTockings after Stroke (CLOTS) 3 was a multicentre, parallel-group, randomised
controlled trial which allocated patients via a central randomisation system to IPC or no IPC. A technician
blinded to treatment allocation performed compression duplex ultrasound (CDU) of both legs at 7–10 days
and 25–30 days after enrolment. We followed up patients for 6 months to determine survival and later
symptomatic VTE. Patients were analysed according to their treatment allocation.
Setting: We enrolled 2876 patients in 94 UK hospitals between 8 December 2008 and 6 September 2012.
Participants: Inclusion criteria: patients admitted to hospital within 3 days of acute stroke and who were
immobile on the day of admission (day 0) to day 3. Exclusion criteria: age < 16 years; subarachnoid
haemorrhage; and contra-indications to IPC including dermatitis, leg ulcers, severe oedema, severe
peripheral vascular disease and congestive cardiac failure.
Interventions: Participants were allocated to routine care or routine care plus IPC for 30 days, or until
earlier discharge or walking independently.
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Main outcome measures: The primary outcome was DVT in popliteal or femoral veins, detected on a
screening CDU, or any symptomatic DVT in the proximal veins, confirmed by imaging, within 30 days of
randomisation. The secondary outcomes included death, any DVTs, symptomatic DVTs, pulmonary emboli,
skin breaks on the legs, falls with injury or fractures and duration of IPC use occurring within 30 days of
randomisation and survival, symptomatic VTE, disability (as measured by the Oxford Handicap Scale),
quality of life (as measured by the European Quality of Life-5 Dimensions 3 Level questionnaire) and length
of initial hospital stay measured 6 months after randomisation.
Results: We allocated 1438 patients to IPC and 1438 to no IPC. The primary outcome occurred in 122
(8.5%) of 1438 patients allocated to IPC and 174 (12.1%) of 1438 patients allocated to no IPC, giving
an absolute reduction in risk of 3.6% [95% confidence interval (CI) 1.4% to 5.8%] and a relative risk
reduction of 0.69 (95% CI 0.55 to 0.86). After excluding 323 patients who died prior to any primary
outcome and 41 who had no screening CDU, the primary outcome occurred in 122 of 1267 IPC
participants compared with 174 of 1245 no-IPC participants, giving an adjusted odds ratio of 0.65
(95% CI 0.51 to 0.84; p= 0.001). Secondary outcomes in IPC compared with no-IPC participants were
death in the treatment period in 156 (10.8%) versus 189 (13.1%) (p= 0.058); skin breaks in 44 (3.1%)
versus 20 (1.4%) (p= 0.002); and falls with injury in 33 (2.3%) versus 24 (1.7%) (p= 0.221). Among
patients treated with IPC, there was a statistically significant improvement in survival to 6 months (hazard
ratio 0.86, 95% CI 0.73 to 0.99; p= 0.042), but no improvement in disability. The direct cost of
preventing a DVT was £1282 per event (95% CI £785 to £3077).
Conclusions: IPC is an effective and inexpensive method of reducing the risk of DVT and improving
survival in immobile stroke patients.
Future research: Further research should test whether or not IPC improves survival in other groups of
high-risk hospitalised medical patients. In addition, research into methods to improve adherence to IPC
might increase the benefits of IPC in stroke patients.
Trial registration: Current Controlled Trials ISRCTN93529999.
Funding: The start-up phase of the trial (December 2008–March 2010) was funded by the Chief Scientist
Office of the Scottish Government (reference number CZH/4/417). The main phase of the trial was funded
by the National Institute for Health Research Health Technology Assessment programme (reference number
08/14/03). Covidien Ltd (Mansfield, MA, USA) lent its Kendall SCD™ Express sequential compression
system controllers to the 105 centres involved in the trial and donated supplies of its sleeves. It also
provided logistical help in keeping our centres supplied with sleeves and training materials relevant to the
use of their devices. Recruitment and follow-up were supported by the National Institute for Health
Research-funded UK Stroke Research Network and by the Scottish Stroke Research Network, which was
supported by NHS Research Scotland.
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Plain English summary
A stroke, due to either a blocked or burst blood vessel in the brain, may cause muscle weakness or loss ofco-ordination. Someone who has a stroke and is unable to walk will usually need to be admitted to
hospital. During their hospital stay, stroke patients who are unable to walk are at risk of developing blood
clots in the veins of their legs (called deep vein thrombosis or DVT for short). These clots can break off and be
carried in the bloodstream to the lungs (known as a pulmonary embolism) to cause breathing problems,
which are sometimes fatal. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial tested whether or not
squeezing the legs with intermittent pneumatic compression (IPC) sleeves reduced the risk of DVT. The trial
included 2876 volunteer patients, half of whom were randomly allocated to receive IPC and the other half to
receive standard care. Patients allocated the IPC sleeve wore it for an average of about 12 days, day and
night, but some wore it for up to 30 days. The patients who received IPC developed clots in their leg veins
less often than those who did not receive IPC. Patients assigned IPC were less likely to die within 6 months of
their stroke. The average cost of IPC is about £65 per patient. In summary, the CLOTS 3 trial has shown that
IPC is an effective and inexpensive way to reduce the risk of DVT in stroke patients and it also improves their
chances of survival.
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Scientific summary
Background
Patients admitted to hospital with a stroke of recent onset are at risk of developing deep vein thrombosis
(DVT) which may be complicated by pulmonary emboli (PEs) and sudden death. The risk of DVT is highest in
patients who are initially immobile; among these patients, it may affect about 20% within the first few weeks
of stroke. Prophylactic anticoagulation reduces the frequency of DVTs (mostly asymptomatic and detected
only by scanning the leg veins), but increases the risk of major bleeds, perhaps explaining why randomised
trials have not shown any improvement in either survival or functional outcomes in survivors. Furthermore,
we have previously shown that, after stroke, graduated compression stockings are not effective for the
prevention of DVT and PE. Intermittent pneumatic compression (IPC) has been shown to reduce the risk of
DVT in patients undergoing surgery but has not been robustly evaluated in hospitalised medical patients,
including those with stroke.
Objectives
To determine whether or not:
(a) IPC applied to the legs of immobile stroke patients admitted to hospital reduces their risk of proximal DVT
(b) IPC reduces the risk of any (proximal or calf vein, symptomatic or asymptomatic) DVTs, PEs or deaths
within the 30-day treatment period
(c) IPC increases the risk of skin breaks, falls or fractures within the 30-day treatment period
(d) IPC use is associated with reductions in venous thromboembolism (VTE) or improvements in survival,
function or quality of life over the first 6 months after stroke
(e) IPC use influences NHS hospital costs and to determine its cost-effectiveness in stroke patients.
Methods
Design overview
The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial is a multicentre, parallel-group trial with
a centralised randomisation system to allocate treatments in a 1 : 1 ratio, which ensures allocation
concealment. It enrolled consenting patients in 94 centres in the UK, from day 0 to day 3 of admission
and allocated them, via the central randomisation system, to IPC or no IPC.
Setting and participants
Between December 2008 and September 2012 we enrolled 2876 patients in 94 hospitals in the UK and
completed follow-up in March 2013. Patients were eligible for inclusion if they were admitted to hospital
within 3 days of an acute stroke (ischaemic or haemorrhagic); patients could be enrolled between the day
of admission (day 0) and day 3 in hospital, and if they were immobile (i.e. unable to walk independently
to the toilet). We excluded patients with subarachnoid haemorrhage and those with severe peripheral
vascular disease, congestive heart failure or skin lesions on the legs which precluded the use of IPC.
Randomisation and interventions
Having obtained consent, the clinician entered a patient’s baseline data into our computerised central
randomisation service via a secure web interface. Once the computer program had checked these baseline
data for completeness and consistency, it generated the patient’s treatment allocation: either ‘routine care
plus thigh-length IPC’ or ‘routine care and no IPC’.
DOI: 10.3310/hta19760 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 76
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi
In patients allocated to IPC, nursing staff applied the Kendall SCD™ express sequential compression system
(Covidien Ltd, Mansfield, MA, USA) with thigh-length sleeves, in accordance with the manufacturer’s
instructions, to both legs. It was worn day and night for 30 days or until a second-screening compression
duplex ultrasound (CDU) had been performed (if after 30 days) or until the patient was independently
mobile, was discharged from the randomising hospital or refused to wear the sleeves or the staff became
concerned about the patient’s skin. We stipulated that both treatment groups should receive the same
routine care that could include, depending on local protocols, early mobilisation, hydration and antiplatelet or
anticoagulant drugs.
Outcomes and follow-up
The primary outcome was the occurrence of either a symptomatic or an asymptomatic DVT in the popliteal or
femoral veins (detected on the first or second CDU performed as part of the trial protocol), or a symptomatic
DVT in the popliteal or femoral veins, confirmed on imaging (either CDU or venography), within 30 days of
randomisation. Secondary outcomes included death, any DVT or PE, skin breaks and falls with injuries or
fractures and duration of IPC use within 30 days and any DVT or PE, survival, functional status [as measured
by the Oxford Handicap Scale (OHS)] or quality of life [as measured by the European Quality of Life-5
Dimensions 3 Level (EQ-5D-3L) questionnaire] at 6 months.
Data collection methods
We aimed to perform CDU of the veins of both legs between 7 and 10 days after randomisation in all
patients and, whenever practical, obtained a second CDU scan between day 25 and day 30. The local
co-ordinator reviewed the medical records and extracted the information needed to complete our
discharge form. We could not blind the local co-ordinator to group allocation. The discharge form included
checkboxes to record the secondary outcomes and adverse events.
Approximately 6 months after randomisation, we sent a postal questionnaire to each patient’s general
practitioner to establish the patient’s vital status and the occurrence of DVTs or PEs since hospital discharge.
We followed up surviving patients 6 months after enrolment by postal questionnaire; the chief investigator
(MD) interviewed non-responders by telephone, blind to treatment allocation. The questionnaire included
items related to a patient’s living circumstances, disability (OHS) and health-related quality of life (EQ-5D-3L).
Statistical analysis
We estimated that we would need 2800 patients to provide 90% power (α= 0.05) to identify a 4%
absolute reduction in our primary outcome (i.e. 12% to 8%).
For the purposes of all analyses, we retained participants in the treatment group to which they were originally
assigned. We calculated the absolute difference in proportion of patients with an outcome between groups
and the 95% confidence intervals (CIs). We compared the proportion with primary or secondary outcomes
with odds ratios (ORs) and 95% CIs adjusted with logistic regression for the four variables included in our
minimisation algorithm (predicted stroke outcome, delay from stroke onset to randomisation, ability of the
patient to lift both legs off the bed and use of anticoagulants or alteplase).
Economic analyses
Economic analysis of trial treatment effects involved a within-trial evaluation of cost-effectiveness. A NHS
hospital perspective was adopted for assessing resource use and costs. Patient-specific hospital resource
was measured using the duration of stay for the index episode following randomisation.
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Ethics and consent
The protocol was approved by the Scotland A Multicentre Research Ethics Committee (08/MREC00/73) and
the Newcastle and North Tyneside 1 Research Ethics Committee for England (08/H0906/137). The study
was jointly sponsored by the University of Edinburgh and NHS Lothian.
Role of the funding sources
The funders of the study, including Covidien Ltd, had no role in data collection, storage or analysis,
drafting of this report or the decision to publish. We allowed them to comment on the draft manuscript
prior to final submission.
Results
Between 8 December 2008 and 6 September 2012, 2876 patients were enrolled in 94 centres in the UK
and an additional 11 centres took responsibility for delivering the allocated treatment and follow-up for
patients who were transferred from the randomising hospitals. Of the 2876 patients enrolled, 1438 were
randomly assigned to receive IPC and 1438 to receive no IPC. The patients’ baseline characteristics were
well balanced between treatment groups. Use of antiplatelet medication and prophylactic-dose heparin or
low-molecular-weight heparin after randomisation was very similar in both treatment groups. The mean
duration of IPC use was 11.7 days [standard deviation (SD) 10.6 days] and the median duration was 8 days
[interquartile range (IQR) 3–20 days]. Perfect adherence was achieved in 378 (26.3%) of the 1438 patients
in the IPC group. The mean adherence was 55.6% (SD 38.5%) and the median adherence was 55.5%
(IQR 16.7–100%).
The primary outcome occurred in 122 (8.5%) of the 1438 patients allocated to IPC and in 174 (12.1%)
of the 1438 patients allocated to no IPC, giving an OR of 0.65 (95% CI 0.51 to 0.84; p= 0.001) after
adjustment for baseline variables. The absolute risk reduction was 3.6% (95% CI 1.4% to 5.8%). The
primary outcome was confirmed in 276 (93%) of the 296 patients by central review of the CDU images
and in the remaining 20 (7%) patients by the local clinical radiologist’s report of the CDU. To allow for any
observer bias in detecting symptomatic DVTs not detected on routine screening CDU, we repeated the
primary analysis excluding those primary outcomes where a DVT was suspected before the CDU (n= 22).
The estimates of effect were unchanged. In our prespecified subgroup analyses, we noted no significant
interactions between any of the subgroups and the effect of treatment on the primary outcome.
For the secondary outcomes, there were significant reductions in the outcomes of any (symptomatic or
asymptomatic involving proximal or calf veins) DVT [IPC, n= 233 (16.2%), vs. no IPC, n= 304 (21.1%);
OR 0.72, 95% CI 0.60 to 0.87] and symptomatic (including proximal or calf) DVT [IPC, n= 66 (4.6%),
vs. no IPC, n= 90 (6.3%); OR 0.72, 95% CI 0.52 to 0.99]. In some patients, calf veins could not be
visualised fully: the first CDU was unable to exclude an isolated calf DVT in 615 (47%) of 1315 patients in
the IPC group and in 596 (46%) of 1305 patients in the no-IPC group. Among patients in whom CDU was
repeated, we were unable to exclude an isolated calf DVT in 453 (47%) of 955 patients in the IPC group
and in 451 (48%) of 938 patients in the non-IPC group. Patients allocated to IPC had significantly more
skin breaks than patients allocated to no IPC [IPC, n= 44 (3.1%), vs. no IPC, n= 20 (1.4%); OR 2.23,
95% CI 1.31 to 3.81]. The risk of falls with injury [IPC, n= 33 (2.3%), vs. no IPC, n= 24 (1.7%); OR 1.39,
95% CI 0.82 to 2.37] or fractures [IPC, n= 4 (0.3%), vs. no IPC, n= 4 (0.3%)] within 30 days did not
differ between groups. However, the reporting of these secondary outcomes and adverse effects in
hospital was based on case note review and was not masked to treatment allocation. These data for
adverse events are therefore prone to ascertainment bias. We noted non-significantly fewer deaths from all
causes within 30 days among those allocated to IPC than among those allocated to no IPC [IPC, n= 156
(10.8%), vs. no IPC, n= 189 (13.1%); OR 0.80, 95% CI 0.63 to 1.01]. The Cox proportional hazards
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model, adjusted for the factors included in our minimisation algorithm, showed a reduced probability of
death up to 6 months after randomisation in those allocated IPC with a hazard ratio of 0.86 (95% CI 0.74
to 0.99; p= 0.042).
At 6 months, there were no statistically significant differences in patients’ functional status or quality of
life. There was no significant gain in quality-adjusted survival. The direct cost of preventing a DVT was
£1282 (95% CI £785 to £3077). We found no evidence of an excess of DVTs or PEs in the post-treatment
period to indicate that IPC simply deferred events.
Conclusions
The CLOTS 3 trial has shown that IPC applied to immobile stroke patients soon after admission to hospital
significantly reduces the risk of proximal DVT, symptomatic DVTs and any DVTs including those affecting the
calf. We were unable to demonstrate a statistically significant reduction in PEs. Although there was a
significant excess of skin breaks and a non-significant excess of falls with injury, the absolute risk of these
adverse events was low, and most adverse events were not clearly attributable to the IPC. Fewer patients
allocated to the IPC group died (both within 30 days and up to 6 months after randomisation) than died in
the no-IPC group, although these differences were not statistically significant. However, a more sensitive and
prespecified analysis of the hazard of death within the first 6 months, adjusted for baseline covariates,
demonstrated that the relative hazard of death was reduced by about 14%, which was statistically
significant (p= 0.042).
Further research is needed to evaluate the effectiveness of IPC in other groups of hospitalised medical
patients at high risk of VTE and, ideally, to show whether or not IPC reduces deaths from all causes as it
appears to do after stroke in the CLOTS 3 trial. In addition, under trial conditions, adherence to IPC was
modest and it is likely that this reduced the size of the effect observed. Research into methods to improve
adherence to IPC might provide information which would increase the benefits of IPC in stroke patients.
Trial registration
This trial is registered as ISRCTN93529999.
Funding
The start-up phase of the trial (December 2008–March 2010) was funded by the Chief Scientist Office of the
Scottish Government (reference number CZH/4/417). The main phase of the trial was funded by the National
Institute for Health Research Health Technology Assessment programme (reference number 08/14/03).
Covidien Ltd (Mansfield, MA, USA) lent its Kendall SCD™ express sequential compression system controllers
to the 105 centres involved in the trial and donated supplies of its sleeves. It also provided logistical help in
keeping our centres supplied with sleeves and training materials relevant to the use of their devices.
Recruitment and follow-up was supported by the National Institute for Health Research-funded UK Stroke
Research Network and by the Scottish Stroke Research network, which was supported by NHS
Research Scotland.
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Chapter 1 Introduction
In 2005, a House of Commons Health Committee highlighted the very large number of patients dying in UKhospitals from venous thromboembolism (VTE) and called for more effective prophylaxis.1 Studies reported
since 1985 have shown that deep vein thrombosis (DVT) is particularly common in patients who have suffered
a recent stroke.2 Patients with a history of VTE and significant weakness of the leg and who are immobile
appear to be at the greatest risk.3 Studies with magnetic resonance imaging demonstrated DVT in 40%
of stroke patients and above-knee DVT in 18% of patients within 3 weeks of stroke.4 Studies using less
sensitive screening techniques, such as compression duplex ultrasound (CDU), suggest a lower frequency
of above-knee DVT (about 10%), although the types of patients included and the duration and timing of
follow-up influences these estimates.5 Clinically apparent DVT, confirmed on investigation, is less common
than DVT identified through screening; however, DVT may not be recognised and may cause important
complications including pulmonary embolism (PE), sudden death and, in the longer term, post-phlebitis
leg syndrome. PE is an important cause of preventable death after stroke.2 Clinically evident PE has been
variably estimated to affect 1–16% of patients in prospective trials6 and 3–30% of patients in observational
studies.7 In the Clots in Legs Or sTockings after Stroke (CLOTS) 1 trial, about 5% of patients developed
symptomatic DVT and 1.5% had a confirmed PE in the first month after stroke.8 The rate of PE is likely to be
underestimated because PEs are not routinely screened for and autopsies are rarely performed. Many patients
who have pneumonia or unexplained fever may actually have PEs.9 Fifty per cent of patients who die after
an acute stroke showed evidence of PE on autopsy.10 Studies, such as the CLOTS 1 trial, which screen for
DVT may underestimate the clinical importance of VTE because patients are usually treated while still
asymptomatic and so their risk of developing symptomatic DVT and PE is reduced.
A number of interventions have been used to reduce the risk of DVT, as summarised in the following sections.
Anticoagulants
A Cochrane systematic review showed that both low- and medium-dose subcutaneous heparin reduces
the risk of DVT, and probably PE, in patients with acute ischaemic stroke.6 However, evidence from the
International Stroke Trial11 showed that even low-dose heparin (5000 units twice daily) is associated with a
significant excess of symptomatic intracranial and extracranial bleeds which offset any other benefits heparin
may have on recurrent ischaemic stroke and fatal PE. A systematic review of randomised trials testing
anticoagulation for VTE prophylaxis in stroke patients focused on only symptomatic events: deaths, DVT,
PE, fatal PE and bleeds.12 The estimates of treatment effect, expressed as events avoided or caused per
1000 patients treated, are shown in Table 1. This review also compared the effect of low-molecular-weight
heparins (LMWHs) with the effect of unfractionated heparin. The LMWH was associated with fewer DVTs,
but no significant differences in other clinical outcomes.
TABLE 1 Benefits and harms associated with heparin and LMWH use in patients with ischaemic stroke (based on
data from Lederle et al.12)
Outcome
Number
of trials
Number of outcomes/
number treated Outcomes avoided (–)
or caused (+) per
1000 patients treated 95% CIHeparin No heparin
Death 8 496/5276 990/10,129 –9 –29 to 18
PE 5 39/5015 95/9847 –3 –5 to 0
Symptomatic DVT 1 0/101 1/105 –9 –10 to 57
Major bleeding 8 79/5276 89/10,129 +6 2 to 12
CI, confidence interval.
DOI: 10.3310/hta19760 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 76
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
Graduated compression stockings
Although graduated compression stockings (GCSs) seem to reduce the risk of DVT in patients undergoing
surgery,13,14 the CLOTS 1 trial showed that thigh-length GCSs were not associated with a clinically useful
reduction in the risk of post-stroke DVT [absolute reduction in risk of proximal DVT 0.5%, 95% confidence
interval (CI) –1.9% to 2.9%].8 Moreover, use of GCSs was associated with an increase in the risk of skin
breaks on the legs. A Cochrane review of the effectiveness of physical means of reducing the risk of VTE
after stroke identified only one other trial of GCSs.15,16 The two trials included a total of 2615 patients with
stroke. The use of GCSs was not associated with any significant effect on DVT [odds ratio (OR) 0.88,
95% CI 0.72 to 1.08] or death (OR 1.13, 95% CI 0.87 to 1.47).
Intermittent pneumatic compression
Intermittent pneumatic compression (IPC) is achieved by means of a pair of inflatable sleeves which are
wrapped around the legs and are secured by hoop-and-loop fastener and attached via flexible tubing to a
small bedside electric pump. Different manufacturers produce systems with different characteristics, but it
is unclear whether or not these influence the effect on risk of VTE.17 The sleeves may be short (or below
knee), wrapping around just the lower leg, or long (thigh length) to wrap around the thigh as well. Some
types provide compression to the foot only. They are inflated one side at a time to compress the legs at
intervals. Some types inflate sequentially, first around the lower leg and then the upper, to ‘milk’ the blood
from the leg and increase venous flow. Others compress along the length of the sleeves at the same time
(so-called single compression). Some inflate rapidly, others slowly. The frequency of inflation can be fixed
or may vary depending upon the rate of venous refill. IPC is thought to reduce the risk of venous
thrombosis by:
l increasing the flow of venous blood through the deep veins of the leg to reduce the likelihood
of thrombosis
l stimulating release of intrinsic fibrinolytic substances.18
Intermittent pneumatic compression has mainly been used in surgical patients during and immediately
after operations. One systematic review identified 22 randomised controlled trials (RCTs) of IPC, which
included a total of 2779 patients.13 Use of IPC was associated with a 64% reduction in the odds of DVT
(p< 0.00001). This review concluded that a priority for future research was trials of ‘prevention of venous
thromboembolism with mechanical methods among high-risk medical patients (such as those with
stroke)’.13 Another, more recently published, systematic review identified 40 RCTs comparing IPC with
No IPC.19 These trials included a total of 7252 patients, were of very variable quality and included mostly
surgical patients. IPC was more effective than no-IPC prophylaxis in reducing DVT [7.3% vs. 16.7%;
absolute risk reduction (ARR) 9.4%, 95% CI 7.9% to 10.9%; relative risk 0.43, 95% CI 0.36 to 0.52;
p< 0.01; I2= 34%] and PE (1.2% vs. 2.8%; ARR 1.6%; 95% CI 0.9% to 2.3%; relative risk 0.48; 95% CI
0.33 to 0.69; p< 0.01; I2= 0%). This review also showed that IPC was also more effective than GCS in
reducing DVT and appeared to be as effective as pharmacological thromboprophylaxis but with a reduced
risk of bleeding (relative risk 0.41, 95% CI 0.25 to 0.65; p< 0.01; I2= 0%). Adding pharmacological
thromboprophylaxis to IPC further reduced the risk of DVT (relative risk 0.54, 95% CI 0.32 to 0.91;
p= 0.02; I2= 0%) compared with IPC alone.
The Cochrane systematic review of the effectiveness of physical means of reducing the risk of VTE after
stroke identified only two small RCTs of IPC including just 177 patients in total.15 IPC was associated with a
non-significant trend towards a lower risk of DVTs (OR 0.45, 95% CI 0.19 to 1.10) with no evidence of an
effect on deaths (OR 1.04, 95% CI 0.37 to 2.89).
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Thus, the available evidence confirmed that after stroke, even applying current prophylactic strategies, the
risk of VTE was substantial. The available data suggested that IPC is a promising but unproven and rarely
used intervention in the UK. The CLOTS 3 trial aimed to:
1. establish whether or not the routine application of IPC to the legs of immobile stroke patients reduces
their risk of DVT and PE
2. determine whether or not IPC adds to the benefits of routine care, which often includes good
hydration, early use of aspirin and mobilisation
3. quantify any risks of IPC when applied to stroke patients
4. estimate the cost-effectiveness of IPC which would help health service planners decide whether or not
IPC should be offered routinely in the UK NHS
5. provide robust estimates of the effectiveness of IPC in stroke patients which might be extrapolated to
other groups of medical (rather than surgical) patients at high risk of VTE.
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Chapter 2 Methods
Design overview
The CLOTS 3 trial was a multicentre, parallel-group trial with a centralised randomisation system to allocate
treatment in a 1 : 1 ratio, which ensured allocation concealment. Its methods were very similar to those of
CLOTS trials 1 and 2.3,20 We aimed to blind the ultrasonographers who carried out the imaging to detect
DVTs but were unable to blind the patients and their caregivers to allocation group because of the nature
of the intervention. The multicentre research ethics committees in the UK and the local ethics committees
in all contributing centres approved our protocol. We obtained written informed consent from all patients
or, for patients lacking mental capacity, from the patients’ personal legal representatives. The trial was
registered as [International Standard Randomised Controlled Trial Number (ISRCTN) 93529999].
Setting
Our collaborators in 105 centres in the UK aimed to enrol and/or follow up at least 2800 patients. To
participate, hospitals had to have a local principal investigator who took responsibility for the trial governance;
a well-organised inpatient stroke service; nursing staff trained in the use of IPC; and a diagnostic ultrasound
department which routinely performed CDU.
Participants
Inclusion criteria
Any patient admitted to hospital within 3 days of a clinical stroke fulfilling the World Health Organization
criteria and who was not able to get up from a chair/out of bed and walk to the toilet without the help of
another person.
Patients could be randomised from day 0 (day of admission) to day 3 of hospital admission. Any patient
who had a stroke during hospital admission was eligible until day 3 from the stroke onset (day 0). Stroke
should have been the most likely clinical diagnosis, but it was not necessary for a visible infarction to be
seen on a brain scan.
Exclusion criteria
l Patients under 16 years of age.
l Patients with stroke due to subarachnoid haemorrhage.
l Patients who, in the opinion of the responsible clinician/nurse, were unlikely to benefit from IPC – for
instance, this would include patients who were expected to mobilise or die within the next day.
l Patients with contraindications to the use of IPC. Contraindications included:
¢ local leg conditions with which the IPC sleeves would interfere such as leg ulcers or dermatitis
¢ severe arteriosclerosis, as indicated by absence of pedal pulses or history of definite
intermittent claudication
¢ massive leg oedema or pulmonary oedema from congestive heart failure.
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l Patients who already had swelling or other signs of an existing DVT. Such patients could be recruited
once a DVT had been excluded by normal D-dimers or CDU. There was a concern that the application
of IPC to patients who may already have a DVT might displace the thrombus and increase the risk of
PE. However, this potential risk has not been documented in the RCTs so far. We have not identified
any case reports that provide convincing evidence that this has occurred.
Inclusion in another research study, including another RCT, did not automatically exclude a patient from
participating in CLOTS 3. As long as inclusion in the other study would not confound the results of CLOTS 3,
co-enrolment was permissible. In addition, local researchers had to avoid overburdening their patients.
Patients were not co-enrolled in another research study that aimed to test an intervention intended to
reduce the risk of VTE.
We did not require local research teams to maintain a screening log, although many did because it was
required by the UK National Institute for Health Research stroke research networks. First, our view is that
maintenance of a screening log diverts valuable resource away from enrolment, data collection and other
important aspects of the trial procedures. Second, given that almost inevitably only a small proportion of
potentially eligible patients are enrolled, screening logs do not provide useful data on which to judge the
generalisability (external validity) of trial results. Finally, if screening logs are to be robust they need to
include patient identifiers, to avoid double counting; the legality of collecting and storing this personal and
sensitive information (patient identifier and name of trial is enough to indicate the patient’s medical
diagnosis) without obtaining informed consent is questionable.
Consent
The patients, or their legal representatives, were approached by a member of the clinical team looking
after that patient to ascertain their interest in participating in the CLOTS 3 trial or to obtain their
permission to pass their details onto any research staff involved. Written informed consent was sought
wherever possible. If this was not possible, the randomising clinician or nurse could obtain witnessed
verbal consent. Patients or legal representatives were given enough time to consider the trial fully and ask
any questions they may have had about the implications of the trial.
Randomisation
Having obtained consent, the clinician entered the patient’s baseline data onto a randomisation form
(see Appendix 2) and then into a computerised central randomisation service via a secure web interface
or a touch-tone telephone system. We encouraged clinicians to enrol patients as early as possible, as
prophylaxis for DVT is likely to have a greater effect if started early. Once the computer program had
checked these baseline data for completeness and consistency, it generated that patient’s treatment
allocation to either ‘routine care plus IPC‘ or ‘routine care alone’. The system applied a minimisation
program to achieve balance for four prognostic factors:
1. delay since stroke onset (day 0 or 1 vs. days 2–7)
2. stroke severity (using a validated prognostic model21 which includes the following factors: age;
prestroke dependency in activities of daily living; living with another person prior to stroke; able to
talk and orientated in time, place and person; and able to lift both arms to horizontal position
against gravity)
3. severity of leg paresis (able or not to lift leg off the bed)
4. use of heparin, warfarin or thrombolysis at the time of enrolment.
METHODS
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As simple minimisation can theoretically lead to alternation of treatment allocation, our system also
incorporated a degree of random allocation, that is it allocated patients to the treatment group that
minimises the difference between the groups with a probability of 0.8 rather than 1.0.22 This helped to
guarantee allocation concealment.
The interventions
In the IPC group we applied the Kendall SCD™ Express system (Covidien Ltd, Mansfield, MA, USA) using
thigh-length sleeves only (Figure 1). Initially, we used the standard sleeves, but during the study we
switched to the Comfort™ sleeves (Covidien Ltd, Mansfield, MA, USA), which were designed to improve
adherence while delivering the same pattern of compression. These devices deliver sequential compression,
first around the distal calf, then proximal calf and then the thigh. Compression is circumferential
(i.e. around the whole circumference of the leg) and sleeve inflation is gradual compared with some types of
IPC. The maximum pressure is 45mmHg. The compression is delivered to one leg at a time at a frequency
which depends on the ‘venous refill time’. When the leg is compressed, its volume is reduced. Between
compressions the veins refill and the volume of the leg increases. The changes in volume are detected by
the IPC controller, which detects movement of air between the sleeves and the controller. The frequency
of compression is higher if venous refill is faster, such as when the legs are dependent. This system aims to
maximise venous flow.
FIGURE 1 The Kendall SCD™ Express system used in the trial. This patient is wearing thigh-length Comfort™ sleeves.
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If allocated IPC, nursing staff sized, fitted and applied the sleeves, based on the manufacturer’s
instructions, to both legs as soon as possible after the randomisation telephone call. The IPC sleeves were
meant to be worn both day and night, while the patient was in the bed or chair for 30 days from
randomisation, or until a second-screening CDU had been performed (if after 30 days). They could be
removed earlier for any of the following reasons:
l The patient was independently mobile around the ward (i.e. could get up from a chair/out of bed and
walk to the toilet without the help of another person).
l The patient was discharged from the participating hospital. If the patient was transferred to a
rehabilitation unit where it was practical to continue the IPC and monitor its use appropriately, then
IPC could be continued until the patient was independently mobile, or declined to continue or until
an adverse effect of IPC occurred. If IPC could not be continued after transfer to a rehabilitation unit,
a discharge form was completed at the time of transfer to the rehabilitation unit.
l The patient declined to continue to have IPC applied.
l Health-care staff identified any adverse effect of the IPC (such as pressure ulcers on the legs, falls due
to the IPC) which they judged made continued application of the IPC unwise.
If the IPC was removed for any other reason, for example to check the legs, or for bathing or for screening
CDU, then the IPC was to be re-applied as soon as possible. If the sleeves became soiled, they were to
be replaced with new sleeves as soon as possible. If a reason to remove the IPC sleeve from one leg
developed, treatment to the other leg could continue; however, information on how often this occurred
was not captured systematically.
Our recruitment co-ordinator (CW) and representatives of Covidien Ltd provided onsite training to nursing
staff in the correct sizing, fitting and monitoring of IPC. This was supplemented by a training video and
web-based training. We asked nursing staff to record their use of IPC on the medication chart to increase
compliance and to aid monitoring. We stipulated that both treatment groups should receive the same
medical care, which could include, depending on local protocols, early mobilisation, hydration and
antiplatelet or anticoagulant drugs. The local co-ordinator, who was not blinded to treatment allocation,
extracted information from the medication charts on the compliance with IPC and use of antiplatelet
and anticoagulant drugs during the admission and recorded this on our hospital discharge form
(see Appendix 2); therefore, we could check that these aspects of medical care were used equally in
the treatment groups.
Primary outcome
The primary outcome was the occurrence of either a symptomatic or asymptomatic DVT in the popliteal
or femoral veins (detected on the first or second CDU performed as part of the trial protocol) or a
symptomatic DVT in the popliteal or femoral veins, confirmed on imaging (either CDU or venography)
within 30 days of randomisation. We focused on proximal DVTs because they are much more reliably
detected by ultrasound and are generally regarded as clinically more important.23–25
Secondary outcomes
In hospital or within 30 days:
l death within 30 days
l presence of definite or probable DVT in the popliteal or femoral veins detected on a screening CDU
scan which had not been suspected clinically before the scan
l definite (i.e. excluding probable DVTs) symptomatic or asymptomatic DVT in the popliteal or femoral
veins detected on either a CDU scan or contrast venography or magnetic resonance direct thrombus
imaging within 30 days of randomisation
METHODS
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l any definite or probable symptomatic or asymptomatic DVT (i.e. including DVTs which only involve the
calf veins)
l confirmed fatal or non-fatal PE
l adherence to allocated treatment
l adverse events related to IPC within 30 days of randomisation.
At 6 months:
l death from any cause
l any confirmed symptomatic or asymptomatic DVT or PE occurring between randomisation and
final follow-up
l any symptomatic DVT or PE occurring between randomisation and final follow-up
l functional status (as measured by the Oxford Handicap Scale)26
l place of residence
l health-related quality of life [European Quality of Life-5 Dimensions 3 Level (EQ-5D-3L) questionnaire].27,28
Adverse events
Stroke is a serious medical condition. About 20% of hospitalised patients are expected to die. Serious
medical complications are common. The CLOTS 3 trial evaluated IPC, a non-drug intervention which has a
CE mark and has been approved for the purpose of reducing the risks of VTE. The risks associated with IPC
and participation in the trial were judged to be very small and generally predictable, for example skin
problems on legs or falls resulting in injury. It would be relatively straightforward to attribute any serious
adverse event to the IPC. In this trial we therefore did not require routine reporting of any adverse events,
as this was unlikely to be informative and would have placed an unnecessary burden on the local
researchers, which would have compromised the practicality of the trial. We did require prompt reporting
of primary and secondary outcomes on the radiology report form (within 2 working days), discharge
form (within 10 working days), general practitioner (GP) questionnaire and hospital follow-up forms
(see Appendix 2).
The following were reported on the radiology report form, discharge form or GP questionnaire (if patient
had been discharged) or hospital 6-month follow-up form (if the patient was still in hospital):
l any confirmed DVT
l any confirmed PE
l any fall associated with significant injury occurring within 30 days of enrolment (when IPC might still be
applied); an injury requiring investigation or specific treatment, which prolongs hospitalisation, or which
leads to death, temporary or permanent disability
l any damage to the skin of the legs including necrosis or ulcers occurring within 30 days of enrolment
l reason(s) for prematurely stopping the IPC.
The following were expected complications of stroke and its comorbidities and did not need to be
reported as adverse events:
l deaths, which were reported as outcome events on the discharge or 6-month follow-up forms
l infections other than those affecting the skin of the legs
l further vascular events (including recurrent strokes, myocardial infarction and bowel ischaemia)
l cardiac, renal or liver problems
l epileptic seizures
l spasticity or contractures
l painful shoulder and other joint problems
l mood disturbances.
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Any other adverse events which the investigator felt might be a result of either the treatment or
participation in the trial were to be reported within 10 working days to the co-ordinating centre. A serious
adverse event (i.e. one resulting in death, is life-threatening or which results in significant disability or
incapacity or prolongation of hospitalisation) was to be reported immediately on a serious adverse events
form online or by fax. Serious adverse events attributed to the trial treatment or participation in the trial
were reported to the Data Monitoring Committee (DMC), trial sponsors and ethics committees.
Follow-up
Detection of deep vein thrombosis
Patients should have had a CDU of the veins in both legs between day 7 and day 10 and usually between
day 25 and day 30. We defined minimum acceptable technical standards for ultrasound equipment and
stipulated that the trial ultrasonographers should have performed CDU to diagnose DVTs as part of a
clinical service. We asked them to visualise the popliteal and femoral veins in both legs but did not insist
that they routinely visualised the six deep veins in the calf, as detecting thrombosis in these is far less
reliable. In addition, insisting on scanning of calf veins increases the time required for scanning, which
might have impacted on the ability of centres to participate. We obtained a hard copy of scans in those
patients with our primary outcome in order to enable our trial radiologist (JR), who was blinded to group
allocation, to verify each primary outcome. We did not perform central verification of negative scans
because, with ultrasound techniques, meaningful verification of static images is difficult. If no image
was available we verified the scan result by obtaining a local radiologist’s clinical report. If the second
ultrasound was delayed to more than 30 days and showed a popliteal or femoral DVT, it was included in
the primary outcome. However, we did not include in our primary outcome a proximal DVT that came
to attention only because symptoms started more than 30 days after enrolment, as this might have
introduced bias because researchers unblinded to treatment allocation might theoretically include later
clinical outcomes in one group preferentially.
Where the randomising person judged that it was likely to be impractical to perform a CDU between day
25 and day 30, he or she could, prior to randomisation, stipulate that a CDU would be performed only
between day 7 and day 10. This might have been the case if the patient was likely to be discharged home
to another region or transferred to a rehabilitation facility that did not have use of CDU facilities and was
remote from the randomising centre. This was done to minimise losses to follow-up which, if unequal
between the two treatment groups, could bias the trial results.
If a definite above-knee DVT was detected on the first screening CDU, that is the patient had our primary
outcome, then the second screening CDU was no longer required.
Intermittent pneumatic compression was removed completely before the patient left the ward to undergo
CDU, to ensure optimal blinding of the primary outcome measure. The CDU operator was asked to guess
which treatment group the patient was in prior to the examination to estimate the effectiveness of
blinding. In those allocated IPC, the sleeves were immediately re-applied on the patient’s return to the
ward after the screening CDU.
In-hospital follow-up
The local co-ordinators completed a discharge form (see Appendix 2) for all randomised patients on
discharge from the randomising centres or in the event of earlier death. We could not blind the local
co-ordinators to group allocation. If a patient was transferred to a rehabilitation unit on a different site to
the randomising centre, and it was impractical to continue the allocated treatment or its monitoring while
the patient was in that unit, a discharge form was completed on transfer to that unit.
METHODS
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The data collected at hospital discharge by the unblinded local co-ordinator included:
l Use of heparin, LMWHs, warfarin and antiplatelet drugs during admission to monitor the components
of routine care and to ensure equal use in the two treatment arms. However, an imbalance of heparin
or LMWH and warfarin might occur if IPC is effective as more patients in the control arm would receive
these drugs to treat the excess of VTE. The indications for their use were therefore recorded. The
timing of starting and duration of anticoagulation were not recorded.
l Use of full-length or below-knee GCSs to monitor the components of routine care and to ensure equal
use in the two treatment arms. Again the timing of initiation and duration of use were not recorded.
l Adherence to treatment allocation and use of IPC. We captured the date any IPC was first applied and
the date it was last applied. We also asked the local researcher to record the number of days between
these dates when the IPC was not applied at all. We did not systematically record whether or not the
IPC was applied to one or both legs and how many hours per day it was worn.
l Any clinical DVT or PE requiring treatment.
l Any complications of treatments, in particular skin problems on the legs and falls resulting in injuries
and fractures occurring within the first 30 days after randomisation. Local researchers were asked to
provide the date that each event occurred, and whether or not it was thought likely to be because of
the IPC on the basis of the type of event and its timing.
The discharge form included checkboxes to record these secondary outcomes and adverse events (see
Appendix 2). The date of occurrence of any secondary outcome was recorded along with a free-text
description of the problem. The chief investigator (MD) reviewed these data centrally and coded the events
as far as possible blind to the group allocation.
Later outcomes
The co-ordinating centre telephoned and sent a postal questionnaire to the GPs of all patients who
survived to discharge from hospital about 24 weeks after randomisation. This established that the patient
was alive prior to sending out a follow-up form and to ascertain whether he or she had had any DVT or PE
since discharge from the randomising centre.
Six-month follow-up
The co-ordinating centre sent a postal questionnaire (and one postal reminder and then a telephone
follow-up for non-responders) to those surviving patients who had been discharged. The 6-month
questionnaire (see Appendix 2) aimed to establish:
l the place of residence (own home, with relatives, residential care or nursing home) (as a guide to
resource use)
l their functional status [as measured by the Oxford Handicap Scale (OHS)]
l their current antithrombotic medication regimen
l presence of leg swelling or ulcers which might reflect post-DVT syndrome.
The questionnaire was completed by the patient or, in the case of those who had difficulties which
prevented them doing it themselves, it could be completed by someone close to them. If there was a delay
in completing the questionnaire, no attempt was made to judge retrospectively what the patient’s status
had been at 6 months.
If the patient was still in hospital when the 6-month follow-up was due, the randomising clinician/nurse
was sent a 6-month ‘in-hospital’ follow-up form, which was completed through consultation with the
patient. We checked data centrally for completeness and consistency and sent monthly reports to each
centre with data queries.
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Management of deep vein thrombosis in the trial
If the clinician was satisfied that the patient had a proximal DVT (with or without a confirmatory
venogram), the patient was anticoagulated using subcutaneous heparin/LMWH according to local
protocols as long as there was no contraindication. If only calf vein thrombus was detected (by screening
CDU and/or venography), the responsible clinician could anticoagulate the patient according to local
protocols or, alternatively, arrange follow-up CDU approximately 7 days later to identify any propagation
into the popliteal vein. If definite popliteal or femoral vein thrombus was detected, the patient was
anticoagulated unless contraindicated. Any patient who developed symptoms or signs suggestive of DVT
during their admission was investigated by either CDU and/or venography or magnetic resonance direct
thrombus imaging and treated in accordance with local protocols if the diagnosis was confirmed. Use of
heparin, LMWHs and warfarin to treat DVT and/or PE during admission was recorded on the discharge
form. Timing of any use of anticoagulants during admission but after randomisation was not recorded.
Continued use of IPC in patients with DVT was at the discretion of the responsible clinician.
Sample size
We originally planned to enrol at least 2000 patients. This aimed to give the trial a > 90% power
(α= 0.05) to identify an absolute reduction in risk of our primary outcome of 4% (i.e. a reduction in risk
of our primary outcome from 10% in the no IPC group to 6% in the IPC group). The frequency of our
primary outcome was estimated from the CLOTS trials 1 and 2. We aimed to enrol at least 75% of
patients from day 0 to day 2 after stroke onset. If the proportion enrolled after day 2 exceeded 25%
of the total, then the Trial Steering Committee (TSC) could consider raising the overall target. This aimed
to ensure that we did not miss a real treatment effect because of delays in recruitment.
In October 2010, the frequency of the primary outcome in both groups combined was 12.2%, rather than
the expected 8%. The TSC therefore revised the sample size to 2800 to ensure that the trial maintained
power to detect a 4% absolute difference in proximal DVT (i.e. a reduction from 14% in the routine care
group to 10% in the routine care plus IPC group). The TSC was not aware of any results split by
treatment group.
Statistical analyses
The trial statistician (CG) prepared analyses of the accumulating data which the independent DMC reviewed
in strict confidence at least once per year. No other members of the trial team, TSC or participants had access
to these analyses.
A detailed analysis plan was prepared by the members of the TSC and then published prior to the
completion of enrolment without input from the trial statistician or reference to the unblinded data.29,30
For the purposes of all primary analyses, we retained participants in the treatment group to which they
were originally assigned irrespective of the treatment they actually received. We strived to obtain full
follow-up data on every patient to allow a full intention-to-treat analysis. Inevitably, some patients were
lost to follow-up. If data were unavailable, we excluded these patients from the analyses and conducted
sensitivity analyses to see the effect of these exclusions on our conclusions. For binary outcomes
(e.g. occurrence of a primary or secondary outcome or not), outcomes are presented as ORs and 95% CIs,
adjusted using logistic regression for the factors used in the minimisation algorithm. We calculated
absolute reductions in risk from these values. We converted ORs into relative risks using a standard
method.31 We analysed survival with Cox regression, adjusting for baseline variables included in our
minimisation algorithm. We analysed the OHS in two ways: dichotomised into OHS score of 0–2 versus
3–6 (by logistic regression) and as an ordinal scale (by ordinal regression). The utility based on the EQ-5D-3L
score was compared by a two-sample Wilcoxon test given the non-normal distribution of the data.
METHODS
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Preplanned subgroup analyses
Preplanned subgroup analyses included the effect of treatment allocation on the primary outcome
subdivided by key baseline variables:
l Time from stroke onset to randomisation (day 0 or day 1 vs. days 2–7, and days 0–2 vs. days 3–7). As
DVT may develop very soon after stroke onset and IPC may not influence propagation of thrombus
which has already started, it is plausible that IPC would be more effective if started earlier after stroke.
l Paralysis of leg (able to lift both legs or not?).
l Stroke severity [using a validated prognostic model. Probability of independent survival (OHS score of
< 3)= 0–0.15 vs. > 0.15 (simple six-variable model21)].
l High or low risk of DVT based on the presence of any one or more of the following indicators of a
higher risk of DVT: dependent in activities of daily living (ADL) prior to stroke; prior history of DVT;
unable to lift both arms or unable to lift both legs.3
l Use of heparin, LMWHs, warfarin or thrombolysis at the time of enrolment.
l Haemorrhagic stroke versus ischaemic or unknown pathology.
l Standard versus Comfort™ sleeves.
Subgroup analyses were performed by observing the change in log-likelihood when the interaction
between the treatment and the subgroup was added into a logistic regression model.
Secondary analyses
Intermittent pneumatic compression has usually been used for a relatively short time on perioperative
patients and patients in high-dependency units. In the CLOTS 3 trial, we aimed to maintain the IPC
treatment for up to 30 days, if the patient remained in hospital and was still immobile. However, for a
variety of reasons, the IPC was often terminated earlier than this or it was not applied continuously. In the
CLOTS 1 and 2 trials, 79% of proximal DVTs were detected on the first CDU scan.5 The risk of DVT
seemed to be highest early on, and therefore any prophylaxis might be more effective during this period.
We carried out additional analyses (including all those subgroups identified in the primary outcome) of the
effect of allocation to IPC on the primary outcome occurring within 14 days of randomisation, rather than
30 days. This would, we hoped, to some extent, reduce the impact of patients who required IPC for only a
few days before becoming mobile or adhered to IPC for only a short time. In addition, it would reflect the
practice in many places where acute hospital admission for stroke is short and prophylaxis is applied for
only the first few days. However, it is also possible that prophylaxis for the first 7, 14 or 30 days may
simply defer the onset of DVT. We therefore analysed whether or not there is a difference in frequency of
any symptomatic and/or asymptomatic DVT or PE within 6 months between patients allocated to IPC and
those not.
These statistical analyses were performed using SAS (SAS Institute Inc., Cary, NC, USA).
Research governance
The principal investigator in each centre was responsible for:
l discussing the trial with medical and nursing staff who see stroke patients and ensure that they
remained aware of the state of the current knowledge, the most recent trial protocol and
its procedures
l delegating roles to those with appropriate knowledge and skills
l ensuring that patients admitted with stroke were considered promptly for the trial
l ensuring that the randomisation forms, radiology report forms and discharge forms were completed
and either entered on line or sent to the co-ordinating centre promptly and that copies were kept in a
site file and patient notes
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l ensuring that the trial was conducted in accordance with good clinical practice and fulfilled all national
and local regulatory requirements
l ensuring that the patients’ confidentiality was not breached
l allowing access to source data for audit and verification.
The co-ordinating centre was responsible for:
l providing study materials, a 24-hour randomisation service and helpline
l giving collaborators regular information about the progress of the study
l helping ensure complete data collection at discharge
l responding to any questions (e.g. from collaborators) about the trial
l assuring data security and quality in accordance with good clinical practice and local guidelines
l ensuring trial was conducted in accordance with good clinical practice.
Monitoring
Intermittent pneumatic compression devices carry a CE mark and are licensed for use as prophylaxis for
VTE. In surgical practice, use appears to be associated with a low risk of adverse effects. The trial
procedures were relatively simple and placed only a small burden on the patients. No significant financial
inducements were offered to collaborating centres to encourage their active participation or to reward
high recruitment rates. Central follow-up of all patients at about 6 months after enrolment provided
confirmation of the trial participants identity (hence avoided the need for detailed on-site source data
verification of patient identity, a very resource-intensive activity). After an appropriate risk assessment
process, the Trial Management Group and the trial sponsors judged that the risks of patients being
harmed by the trial interventions were small, any hazard associated with participation in the trial was very
small and the risk of research misconduct was also small. The intensity of on-site monitoring which we
undertook was based on this risk assessment. The co-ordinating centre monitored the completeness,
internal consistency and validity of the data from all trial sites. We used the trial data collected to monitor
adherence to the trial protocol. Our study monitor carried out source data verification in a small random
sample of patients during site visits. If concerns arose as a result of the routine central statistical
monitoring, a more detailed investigation including on-site verification of source data was carried out.32
The trial was jointly sponsored by NHS Lothian and the University of Edinburgh [ACCORD (Academic and
Clinical Central Office for Research and Development)].
Patient and public involvement
Two patient representatives on the TSC provided feedback on our trial materials, procedures and results.
Both had had a stroke and both had worked in nursing in the past; therefore, both were familiar with
the problem of VTE. One worked for the NHS in procurement and was very knowledgeable about NHS
purchasing of GCSs and IPC devices. This proved very valuable to us. She had been eligible for the CLOTS
1 trial but had declined to be enrolled, although she had then agreed to work with us on the TSC of each
of the CLOTS trials. The other had been enrolled in the CLOTS 3 trial during the start-up phase and could
therefore provide personal experience of being a trial participant.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Chapter 3 Trial conduct
Between 8 December 2008 and 6 September 2012, 2876 patients were enrolled in 94 centres in theUK, and an additional 11 centres took responsibility for delivering the allocated treatment and
follow-up for patients who were transferred from the randomising hospital (see Appendix 1).
Recruitment
Funded by the Chief Scientist Office in Scotland, recruitment at the Western General Hospital, Edinburgh,
started in the start-up phase once the CLOTS 1 trial had completed recruitment (in September 2008),
although recruitment into the CLOTS 2 trial continued in other hospitals. The CLOTS 2 trial completed
recruitment in May 2009, after which many centres switched to recruiting into the CLOTS 3 trial. The
CLOTS 3 collaboration was expanded after funding from the Health Technology Assessment programme
was secured in April 2010. The rate of recruitment over time is shown in Figure 2. The recruiting hospitals,
and the number each recruited, are listed in Appendix 1.
The rate of recruitment exceeded our expectations; therefore, we reached our revised target of 2800
approximately 1 year before we had expected to reach our original target of 2000 patients.
Baseline characteristics of patients recruited
The patients’ baseline characteristics are shown in Table 2 and were well balanced between treatment
groups. The patients’ progress through the trial is shown in the CONSORT (Consolidated Standards of
Reporting Trials) diagram (Figure 3).
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FIGURE 2 Recruitment in the CLOTS 3 trial over time.
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TABLE 2 Baseline characteristics of patients enrolled (n= 2876)
Baseline variable IPC (n= 1438) No IPC (n= 1438)
Median age,a years (IQR) 76 (67–83) 77 (68–84)
Mean age, years (SD) 74.2 (12.3) 74.9 (11.9)
Males, n (%) 695 (48.3) 688 (47.8)
Final diagnosis at hospital discharge
Stroke/TIA (definite/probably ischaemic), n (%) 1211 (84.2) 1217 (84.6)
Confirmed haemorrhagic stroke, n (%) 187 (13.0) 189 (13.1)
Unknown type, n (%) 19 (1.3) 14 (1.0)
Non-strokes (included in primary analysis), n (%) 19 (1.3) 18 (1.3)
Missing (no discharge form), n (%) 2 (0.1) 0 (0.0)
Past history and risk factors
Previous DVT or PE, n (%) 66 (4.6) 74 (5.1)
Diabetes mellitus, n (%) 256 (17.8) 247 (17.2)
Peripheral vascular disease, n (%) 24 (1.7) 31 (2.2)
Overweight, n (%) 417 (29.0) 457 (31.8)
Current cigarette smoker, n (%) 250 (17.4) 228 (15.9)
Independent before stroke,a n (%) 1301 (90.5) 1295 (90.1)
Lives alone before stroke,a n (%) 500 (34.8) 503 (35.0)
Indicators of stroke severity
Able to lift both arms off bed,a n (%) 499 (34.7) 502 (34.9)
Able to talk and orientated,a n (%) 886 (61.6) 845 (58.8)
Able to lift both legs off bed, n (%) 494 (34.4) 493 (34.3)
Able to walk without help,a n (%) 0 (0) 0 (0)
Stroke severity – probability of being alive and
independent= 0 to 0.15), n (%)
898 (62.4) 892 (62.0)
Stroke severity – median (IQR) probability of
being alive and independent
0.09 (0.02–0.31) 0.09 (0.01–0.31)
On warfarin at recruitment, n (%) 25 (1.7) 29 (2.2)
On heparin or LMWHs at recruitment, n (%) 86 (6.0) 78 (5.4)
Taken antiplatelet drug in the last 24 hours, n (%) 970 (67.5) 971 (67.5)
Received thrombolysis since admission, n (%) 249 (17.3) 255 (17.7)
On heparin or LMWH or warfarin at recruitment or
received thrombolysis since admission, n (%)
347 (24.1) 352 (24.5)
Delay from stroke to randomisation
0 to 1 day, n (%) 624 (43.4) 620 (43.1)
2 days, n (%) 478 (33.2) 457 (31.8)
≥ 3 days, n (%) 336 (23.4) 361 (25.1)
Second CDU considered unlikely to be practical
at time of randomisation, n (%)
225 (15.6) 215 (15.0)
IQR, interquartile range; SD, standard deviation; TIA, transient ischaemic attack.
a Factors included in model to predict probability of being alive and independent at 6 months.21
Variables in italics were included in minimisation algorithm.
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Patients randomised
(N = 2876)
Allocated no IPC
(N = 1438)
Allocated IPC
(N = 1438)
No first CDU (N = 123)
• Patient died before any 
   CDU, n = 92
• Missing because too ill, 
   n = 5
• Missing because patient
   refused, n = 23
• Missing other, n = 3
No first CDU (N = 133)
• Patient died before any 
   CDU, n = 114
• Missing because too ill, 
   n = 4
• Missing because patient
   refused, n = 13
• Missing other, n = 2
No second CDU (N = 483)
• Patient died before any 
   CDU, n = 127
• Second CDU not planned, 
   n = 225
• Prior primary outcome, 
   n = 45
• Missing because too ill, 
   n = 12
• Missing because patient
   refused, n = 61
• Missing other, n = 13
Withdrew consent,a n = 2 Discharge form missing, n = 1
Patient died before f/u, 
n = 330
Withdrew consent,a n = 6
Form not received, n = 10
Patient died before f/u, 
n = 367
Withdrew consent,a n = 5
Form not received, n = 13
No second CDU (N = 503)
• Patient died before any 
   CDU, n = 163
• Second CDU not planned, 
   n = 215
• Prior primary outcome, 
   n = 67
• Missing because too ill, 
   n = 6
• Missing because patient
   refused, n = 36
• Missing other, n = 16
Complete baseline data
(N = 1438) (100%)
Complete baseline data
(N = 1438) (100%)
Had first CDU
(N = 1305) (90.8%)
Had first CDU
(N = 1315) (91.4%)
Had second CDU
(N = 935) (65.0%)
Had second CDU
(N = 955) (66.4%)
Had discharge 
form returned
(N = 1437) (99.9%)
Had discharge 
form returned
(N = 1436) (99.9%)
Follow-up form
complete
(N = 1058) (73.6%)
Follow-up form
complete
(N = 1098) (76.4%)
Vital status at 
30 days known
(N = 1431) (99.5%)
Vital status at 
30 days known
(N = 1432) (99.6%)
FIGURE 3 The CONSORT diagram (the number screened for eligibility was not collected). a, The number of patients
who withdrew consent is less than the number published in The Lancet.33 The figure includes data only up to the
point at which permission to follow up the patients or to use data was explicitly withdrawn. F/u, follow-up.
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Withdrawal
Patients, or their proxies, were informed at the time they gave consent that they could stop the allocated
treatment at any time, and without giving a reason. They were also told that they could withdraw completely
from the study, although the data collected up to that point would be used in analyses. Unfortunately, local
research teams did not always clearly establish the precise wishes of the patient or proxy. For instance, if the
patient wished to stop receiving the allocated treatment, then this was sometimes interpreted as wishing to
withdraw from the trial completely (implying that the patient would not be followed up). In addition, even
when a patient expressed a wish not to be contacted directly by mail or telephone for follow-up, this did not
necessarily preclude us from establishing their follow-up status through their GP or routine data sources. As a
result, in some cases there was some uncertainty about whether or not we could use certain data items, such
as date of death. In general, we included patients in the analysis unless it was clear from the correspondence
that they did not want anything more to do with the trial. Based on this experience, it is clearly important
that trials are rigorous in defining exactly what the patient wishes to do when they stop the intervention and
whether or not they are also refusing any further contact for follow-up.
Background treatment
The use of antiplatelet medications, prophylactic- and treatment-dose heparin or LMWHs, oral anticoagulants
and GCSs was recorded in both treatment groups on the discharge form by the local co-ordinator. However,
we did not collect the dates that these treatments were given; therefore, we cannot tell if they were given
concomitantly with IPC, if they followed IPC and if any anticoagulation was used in response to the diagnosis
of a DVT or PE. We did not record timing of mobilisation, use of parenteral fluids or any measure of hydration.
Background treatment with antiplatelet medications, anticoagulants and GCSs is shown in Table 3. Use of
prophylactic-dose heparin or LMWHs after randomisation was very similar in the treatment arms (IPC 17.2%
TABLE 3 Post-randomisation use of background treatment in hospital which might affect the frequency of VTE
Background treatment prescribed IPC (n= 1438) No IPC (n= 1438)
Antiplatelet medication, n (%)
Aspirin 1039 (72.4) 1033 (71.8)
Dipyridamole 152 (10.6) 155 (10.8)
Clopidogrel 526 (36.6) 524 (36.4)
Anticoagulation, n (%)
Prophylactic-dose heparin/LMWHs 248 (17.2) 240 (16.7)
Treatment-dose heparin/LMWHs 182 (12.7) 219 (15.2)
Warfarin 292 (20.3) 294 (20.5)
Other oral anticoagulant 10 (0.7) 8 (0.6)
GCSs, n (%)
GCSs worn (any length) 118 (8.2) 42 (2.9)
Thigh-length GCSs worn only 90 (6.3) 22 (1.5)
Below-knee GCSs worn only 17 (1.2) 19 (1.3)
Both thigh-length and below-knee GCSs worn 10 (0.7) 1 (0.1)
GCSs of unknown length 1 (0.7) 0
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vs. no IPC 16.7%). There was a small excess of treatment-dose heparin or LMWHs in the control arm,
probably because DVTs occurred more commonly in that group. The low overall use of GCSs suggests that
most centres were aware of, and accepted, the evidence from the CLOTS 1 trial that GCS use is not
associated with lower risk of DVT. There was a small excess of GCS use in the IPC group, perhaps because
the manufacturer of IPC previously recommended using IPC and GCSs in combination. However, it is possible
that the GCSs were applied after the IPC had been removed or to prevent post-phlebitis leg syndrome.
Adherence
The measurement of adherence to IPC was based on data provided on the hospital discharge form by the
local co-ordinators. In most cases it was based on the recording of IPC use on medication charts completed
by the nurses on the stroke unit. It was not always complete. We attempted to collect the date the IPC was
first applied, the date it was permanently taken off, the number of days between when it was not worn at all,
and the reason why the IPC was stopped, especially if it was stopped prematurely.
In total, 1424 (99.2%) patients were allocated to the IPC group and were treated with IPC at some point
in the first 30 days after randomisation. In the group allocated to no IPC, four patients received IPC at
some point in the first 30 days. Three patients received IPC having been transferred to an intensive care or
high-dependency unit where IPC was standard care, and one received IPC for 3 days because of a mistake
in recording the allocated treatment.
Ideally, we would have defined 100% adherence as wearing IPC sleeves every day (i.e. no days on which
they were not worn) from randomisation until the patient regained mobility, was discharged from a
participating hospital or died or until 30 days or until a delayed second screening CDU. However, the number
of days on which the IPC sleeves were not worn was not well recorded and was sometimes inconsistent with
other data items. We therefore defined 100% adherence as wearing IPC sleeves from randomisation until
the patient regained mobility, was discharged from a participating hospital or died, or until 30 days, or until a
delayed second screening CDU, ignoring the likelihood that some patients would have had the sleeves
removed for some intervening days and may not have worn them on both legs day and night. One hundred
per cent adherence was achieved in 378 (26.3%) of patients in the IPC group. The distribution of percentage
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adherence is shown in Figure 4. The median adherence was 55.7% [interquartile range (IQR) 16.7–100%].
The adherence to the standard and Comfort™ sleeves are compared in Table 4.
The distribution of duration of use in the IPC group is shown in Figure 5. The mean and median duration
of IPC use was 11.7 days [standard deviation (SD) 10.6 days] and 8 days (IQR 3–20 days) respectively.
Table 5 shows the adherence and reason(s) for removal of IPC in the 1438 patients allocated to IPC
(reasons given are not always mutually exclusive).
TABLE 4 Comparison of length of use and adherence in those allocated to wear the standard and Comfort™ IPC
sleeves. (The calculation of percentage adherence ignored the reported number of days when patients did not
wear sleeves because these data were incomplete)
Adherence measure Standard sleeves (n= 834) Comfort™ sleeves (n= 604)
Duration IPC applied (stop date–start date), n (%)
Missing – –
≤ 1 day 140 (16.8) 96 (15.9)
2–5 days 180 (21.6) 145 (24.0)
6–10 days 169 (20.3) 104 (17.2)
11–20 days 138 (16.5) 109 (18.0)
21–30 days 172 (20.6) 138 (22.8)
> 30 days 35 (4.2) 12 (2.0)
Mean duration of IPC use (SD) in days 11.6 (10.7) 11.7 (10.4)
Median duration of IPC use (IQR) in days 8 (3–20) 8 (3–20)
Wore IPC sleeves until death/discharge/mobile/
30 days or later second CDU (i.e. 100% adherence)
222 (26.6) 156 (25.8)
Mean adherence (SD), % of days applied
per protocol
55.5 (39.0) 55.9 (37.9)
Median adherence (IQR) 54.4 (16.7–100.0) 55.9 (16.9–100.0)
SD, standard deviation.
0
5
10
15
Pe
r 
ce
n
t 
(%
)
20
25
< 2 2–5 6–10
Duration (days)
11–20 21–30 > 30
FIGURE 5 The distribution of duration of use of IPC in the group allocated IPC.
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TABLE 5 Adherence to IPC and reasons for removal recorded by local co-ordinator
Use of IPC n (%)
Total number of patients with a completed discharge form 1436 (100)
Wore IPC sleeves at any time in the first 30 days after randomisation 1424 (99.2)
Wore IPC sleeves every day was supposed to according to protocol 378 (26.3)
Removed according to protocol
Patient regained mobility 142 (9.9)
Second CDU delayed after 30 days 33 (2.3)
Completed 30 days of IPC 66 (4.6)
Removed early
Concerns about patient’s skin 62 (4.3)
Patient refused to wear IPC any longer 474 (33.0)
Patient complained of discomfort 189 (13.2)
Other reasons specified by local researchers 535 (37.3)
Change in view of staff 142 (26.5)
Patient/family refused 107 (20.0)
Intermediate-severity skin problems 3 (0.6)
Low-severity skin problems 18 (3.4)
Other leg problems 4 (0.8)
Technical fault with IPC 7 (1.3)
Fall 1 (0.2)
Other events – fractures, stroke, palliative care 3 (0.6)
Confirmed PE 3 (0.6)
Symptomatic/confirmed DVT 3 (0.6)
Change of use because of DVT 41 (7.7)
Incontinence/diarrhoea 18 (3.4)
Transferred/discharged to another unit 79 (14.8)
Administrative error 56 (10.5)
Other – including no reason 50 (9.3)
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Screening compression duplex ultrasounds
The number and proportions of patients having a CDU in each treatment group are shown in the
CONSORT diagram (see Figure 3). The reasons for a missing CDU are also given. Our protocol stated that
CDU should be performed between day 7 and day 10 after randomisation and between day 25 and day
30. The median delay from randomisation to the first CDU was 8 days (IQR 7–10 days) in both treatment
groups. The median delay from randomisation to the second CDU was 28 days (IQR 26–30 days) in both
treatment groups. The actual timing of CDU is shown in Table 6.
Compression duplex ultrasound scans were not available for all surviving randomised patients (see
Figure 3). In addition, we did not stipulate in our protocol that all patients should undergo CDU of the calf
veins. The minimum acceptable CDU image set was one scan visualising the popliteal and more proximal
veins. Therefore, calf veins were not visualised fully in all patients. Among patients who underwent first
CDU, we were unable to exclude an isolated calf DVT in 615 out of 1315 (46.8%) in the IPC group and in
596 out of 1305 (45.7%) in the non-IPC group. Among those who underwent second CDU, we were
unable to exclude an isolated calf DVT in 453 out of 955 (47.4%) in the IPC group and in 451 out of 938
(48.1%) in the non-IPC group.
In the IPC arm, 117 of 1315 (8.9%) patients were wearing IPC sleeves when they attended for their first
CDU and 37 of 995 (3.7%) were wearing IPC sleeves when they attended for their second CDU.
Therefore, the technician was not blinded in 154 (6.7%) of these 2310 CDUs. In addition, among the
remaining 1198 patients who did not attend their first CDU wearing IPC, the technician guessed correctly
they were allocated to IPC in 48 of cases (4%), had no idea in 916 (76.5%) and guessed incorrectly in 219
(18.3%). Of the 918 patients who were not wearing IPC at their second CDU, the technician correctly
guessed the treatment allocated in 33 (3.6%), had no idea in 702 (76.5%) and guessed incorrectly in
171 (18.6%).
In the no-IPC arm, 4 of 1305 (0.3%) patients were wearing IPC sleeves when they attended for their first
CDU and 4 of 938 (0.4%) were wearing IPC sleeves when they attended for their second CDU. At the first
CDU the technician correctly guessed IPC status in 296 (22.7%) patients, had no idea in 970 (74.3%)
patients and guessed incorrectly in 22 (1.7%) patients. At the second CDU, the technician correctly
guessed the treatment allocation in 167 of cases (17.8%), had no idea in 739 (78.8%) and guessed
incorrectly in 17 (1.8%) cases.
TABLE 6 Proportions of patients having CDU as per protocol, earlier or later
Delay from randomisation to CDU IPC, n (%) No IPC, n (%)
Timing of first CDU 1315 (100.0) 1305 (100.0)
< 7 days 17 (1.3) 14 (1.1)
7–10 days 1091 (83.0) 1060 (81.2)
> 10 days 207 (15.7) 231 (17.7)
Timing of second CDU 955 (100.0) 938 (100.0)
< 25 days 9 (0.9) 6 (0.6)
25–30 days 721 (75.5) 737 (78.6)
> 30 days 225 (23.6) 195 (20.8)
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These data suggest that, where centres followed the protocol which required that they remove any IPC
device from the patient before sending them for CDU, blinding was reasonably effective, that is the vast
majority of observers had little idea of the treatment allocation.
Confirmation of primary outcome
Our primary outcome was confirmed in 276 of 296 (93.2%) cases by central review of CDU images by our
radiologist (JR). In the remaining 20 cases (6.8%), the centres were unable to provide an image for central
review. In these cases, the presence of a proximal DVT was confirmed by obtaining the local radiology
report produced for clinical purposes. In the case of some patients, the local co-ordinator or technician had
recorded a proximal DVT on the CDU report form which was entered into our database. These were not
counted as primary outcomes unless the central review or local clinical report confirmed it.
Six-month follow-up
We aimed to follow up all surviving patients at about 6 months after randomisation. The number and
proportions of patients in whom this was achieved in each treatment group are shown in our CONSORT
diagram (see Figure 3). Patients and GPs were initially followed up by postal questionnaire, with a repeat
mailing for non-responders. If no response, or an incomplete response to the postal questionnaire was
received, then the chief investigator (MD) telephoned the respondent to obtain as much information as
possible. The method of follow-up is shown in Table 7.
The timings of the 6-month patient follow-ups are shown in Table 8. As, inevitably, many of the follow-up
questionnaires were not obtained until much more than 6 months later, some patients had died in the
TABLE 8 Distribution of the timing of 6-month (183-day) follow-up in the two treatment groups
Delay since randomisation (days) IPC, n (%) No IPC, n (%)
< 167 6 (0.5) 14 (1.3)
167–183 659 (60.0) 588 (55.6)
184–199 122 (11.1) 119 (11.2)
200–219 224 (20.4) 237 (22.4)
220–239 66 (6.0) 79 (7.5)
≥ 240 20 (1.8) 21 (2.0)
Missing time 1 (0.1) 0 (0)
Total received 1098 1058
TABLE 7 Method of follow-up (based on tick box on data entry screen indicating who had completed the form and
patients’ response to the question ‘Did you complete the form yourself?’)
Method of follow-up IPC (n= 1098), n (%) No IPC, (n= 1058), n (%)
Patient completed postal questionnaire 359 (32.7) 336 (31.6)
Proxy completed postal questionnaire 474 (43.2) 440 (41.6)
Postal completer not recorded 20 (1.8) 24 (2.3)
Telephone interview with patient 112 (10.2) 115 (10.7)
Telephone interview with proxy 108 (9.8) 117 (11.1)
Telephone interview not recorded if patient or proxy 15 (1.4) 15 (1.4)
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period from 6 months to the time when a follow-up questionnaire was obtained. We did not try to
retrospectively code the functional status in such cases. However, it does mean that the number of
patients recorded as having an OHS score of 6 (i.e. dead) at their 6-month follow-up is greater than the
number of deaths which had occurred by 6 months (based on an actuarial analysis).
Causes of death
For patients who died during their initial hospital admission, the local researcher coded the cause of death
on the discharge form. For patients who died after hospital discharge, we aimed to obtain a copy of their
death certificate, supplemented, where possible, by their GP notes or relevant hospital notes. Whenever an
autopsy was carried out we tried to obtain the report. Final cause of death was coded by the Chief
Investigator, usually blind to the treatment allocation. However, attribution of cause of death is notoriously
difficult unless autopsies are performed. These data are reported for completeness, but we do not believe
that any robust conclusions can be drawn from them.
We attempted to detect post-phlebitic leg syndrome by asking about leg swelling and ulcers at the
6-months follow-up. However, these questions were not validated and unlikely to be specific given the
high frequency of swelling in stroke-affected limbs and of leg ulcers of other types.
Close out
After the final follow-up questionnaire had been completed, we sent each principal investigator a close-out
checklist (see Appendix 3) to complete and send back to us. This checklist had been approved by
ACCORD, the sponsor of the trial. Completed checklists were received from 93 (99%) of the 94
randomising hospitals. The remaining hospital, which had withdrawn from the trial before its completion,
had lost all documentation and has instigated an internal inquiry. The trial master file was archived.
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Chapter 4 Results
Results: primary and secondary outcomes – effectiveness
and safety
Primary outcomes
The patients’ outcomes, with respect to our primary outcome, within 30 days of enrolment are shown in
Table 9. The primary outcome occurred in 122 of 1438 patients (8.5%) allocated to IPC and in 174 of
1438 (12.1%) allocated to no IPC, with an OR of 0.65 (95% CI 0.51 to 0.84; p= 0.001) after adjustment
for baseline variables and an ARR of 3.6% (95% CI 1.4% to 5.8%). To allow for any observer bias in
detecting symptomatic DVTs not detected on routine-screening CDU, we repeated the primary analysis
excluding those primary outcomes where a DVT was suspected prior to the CDU (n= 22). The estimates of
effect were unchanged.
Secondary outcomes within 30 days
The frequencies of deaths and other VTE outcomes within 30 days of randomisation are shown in Table 10.
There were significant reductions in ‘any DVT’ (symptomatic or asymptomatic involving proximal or calf
veins) (ARR 4.9%, 95% CI 2.1 to 7.8; p< 0.001) and symptomatic DVT (including proximal or calf)
(ARR 1.7%, 95% CI 0.0 to 3.3; p= 0.045).
There were fewer deaths from all causes within 30 days among those allocated to IPC, but the difference
was non-significant: IPC, 156 (10.8%), versus no IPC, 189 (13.1%; OR 0.80, 95% CI 0.63 to 1.01;
ARR 2.3%, 95% CI to 0.1 to 4.7%; p= 0.057).
Table 11 shows the causes of death among the patients who died within 30 days of randomisation. This
was based on the information provided by the local researchers. Autopsy to confirm the cause of death
was carried out in only 10 (3%) of the patients who died within 30 days (three in the IPC group and seven
in the no-IPC group).
TABLE 9 Primary outcomes (ORs are adjusted for the variables included in the minimisation algorithm, as specified
in the statistical analysis plan, unless stated otherwise)
Outcome
IPC
(n=1438),
n (%)
No IPC
(n= 1438),
n (%)
Absolute risk
difference
(95% CI) OR (95% CI) p-value
Primary outcome (proximal DVT) 122 (8.5) 174 (12.1) –3.6
(–5.8 to –1.4)
– –
Alive and free of primary outcome 1145 (79.6) 1071 (74.5) – – –
Died prior to any primary outcome 147 (10.2) 176 (12.2) – – –
Missing 24 (1.7) 17 (1.2) – – –
Dead and missing excluded (unadjusted) 122/1267
(9.6)
174/1245
(14.0)
–4.3
(–6.9 to –1.8)
0.66
(0.51 to 0.84)
0.001
Primary analysis (dead and missing
excluded)
– – – 0.65
(0.51 to 0.84)
0.001
Dead included with DVT and missing
included with no DVT (unadjusted)
269/1438
(18.7)
350/1438
(24.3)
–5.6
(–8.6 to –2.6)
0.71
(0.60 to 0.86)
0.0002
Dead included with DVT and missing
included with no DVT
– – – 0.71
(0.59 to 0.85)
0.0002
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TABLE 10 Deaths and other VTE outcomes within 30 days of randomisation (ORs are adjusted for the variables
included in the minimisation algorithm, as specified in the statistical analysis plan)
Secondary outcomes by
30 days or later second CDU
IPC
(n= 1438),
n (%)
No IPC
(n= 1438),
n (%)
Absolute risk
difference
(95% CI) OR (95% CI) p-value
Dead by 30 days 156 (10.8) 189 (13.1) –2.3 (–4.7 to 0.1) 0.80 (0.63 to 1.01) 0.057
Symptomatic proximal DVT 39 (2.7) 49 (3.4) –0.7 (–2.0 to 0.6) 0.79 (0.51 to 1.21) 0.269
Asymptomatic proximal DVT 83 (5.8) 125 (8.7) –2.9 (–4.8 to –1.0) 0.65 (0.48 to 0.86) 0.003
Symptomatic DVT (proximal
or calf)
66 (4.6) 90 (6.3) –1.7 (–3.3 to –0.0) 0.72 (0.52 to 0.99) 0.045
Any DVT (symptomatic or
asymptomatic, proximal or calf)
233 (16.2) 304 (21.1) –4.9 (–7.8 to –2.1) 0.72 (0.60 to 0.87) 0.001
All confirmed PE (imaging
or autopsy)
29 (2.0) 35 (2.4) –0.4 (–1.5 to 0.7) 0.83 (0.50 to 1.36) 0.453
Any DVT or confirmed PE 248 (17.2) 325 (22.6) –5.4 (–8.3 to –2.4) 0.72 (0.59 to 0.86) 0.00035
Any DVT or dead 377(26.2) 472 (32.8) –6.6 (–9.9 to –3.3) 0.72 (0.61 to 0.85) 0.00009
Any DVT, PE or dead 391 (27.2) 491 (34.1) –7.0 (–10.3 to –3.6) 0.72 (0.61 to 0.84) 0.00005
TABLE 11 Causes of death within 30 days of randomisation according to local research teams
Cause of death IPC, n (%) No IPC, n (%)
Initial stroke
Neurological 56 (36) 64 (34)
Pneumonia 43 (28) 61 (32)
PE 4 (3) 5 (3)
Recurrent stroke 18 (12) 16 (8)
Coronary heart disease 12 (8) 8 (4)
Other vascular
Cerebrovascular 10 (6) 12 (6)
Bowel ischaemia 1 (1) 0 (0)
Other 0 (0) 7 (4)
Non-vascular
Fall 0 (0) 1 (1)
Carcinoma 2 (1) 2 (1)
Renal failure 1 (1) 1 (1)
Respiratory failure 2 (1) 4 (2)
Sepsis 2 (1) 2 (1)
Other 2 (1) 5 (3)
Uncertain 1 (1) 0 (0)
Missing 2 (1) 1 (1)
Total deaths 156 (100) 189 (100)
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Adverse events
Adverse events, including skins breaks, leg ischaemia, falls and fractures, which might have resulted from
wearing IPC sleeves are shown in Table 12. There was a statistically significant excess of skin breaks on the
legs of patients allocated to IPC [44 (3.1%) vs. 20 (1.4%), p= 0.002] but no significant differences in the
risk of falls with injury or fractures within 30 days. Few of the skin breaks or falls with injury were
attributed by the local researchers to the IPC. The majority of adverse events occurred either when IPC
sleeves had been removed or when skin breaks affected the heels (which are not covered by the IPC
sleeves); therefore, they were unlikely to be caused by the IPC. However, the reporting of secondary
outcomes in hospital and adverse effects was based on case note review and was not blinded to treatment
allocation. These adverse event data are therefore prone to ascertainment bias.
Deaths and venous thromboembolism events up to six months
The deaths and VTE events up to 6 months, including those arising during the first 30 days, are shown in
Table 13. There was no evidence of an excess of VTE events in the post-treatment period to indicate that
IPC simply deferred VTE events.
TABLE 12 Adverse events within 30 days of randomisation (ORs are adjusted for the variables included in the
minimisation algorithm, as specified in the statistical analysis plan)
Outcome
IPC (n= 1438),
n (%)
No IPC
(n= 1438),
n (%)
Absolute risk
difference (95% CI) OR (95% CI) p-value
Potential adverse effects of IPC
Skin breaks 44 (3.1) 20 (1.4) 1.7 (0.6 to 2.7) 2.23 (1.31 to 3.81) 0.002
Skin breaks attributed
to IPC
10 (0.7) 0 (0.0) 0.7 (0.3 to 1.1) – –
Lower limb ischaemia/
amputation
0 (0.0) 2 (0.1) –0.1 (–0.3 to 0.1) – –
Falls with injury in 30 days 33 (2.3) 24 (1.7) 0.6 (–0.4 to 1.6) 1.39 (0.82 to 2.37) 0.221
Falls with injury in 30 days
attributed to IPC
1 (0.1) 0 (0.0) 0.1 (–0.1 to 0.2) – –
Fractures within 30 days 4 (0.3) 4 (0.3) 0.0 (–0.4 to 0.4) – –
TABLE 13 Deaths and VTE events (including those in first 30 days) during 6-month follow-up (ORs are adjusted for
factors included in our minimisation algorithm, as specified in the statistical analysis plan)
Outcome
IPC (n= 1438),
n (%)
No IPC
(n= 1438),
n (%)
Absolute risk
difference (95% CI) OR (95% CI) p-value
Dead by 6 months 320 (22.3) 361 (25.1) –2.9 (–6.0 to 0.3) 0.85 (0.70 to 1.01) 0.059
Any DVT 240 (16.7) 312 (21.7) –5.0 (–7.9 to –2.1) 0.72 (0.60 to 0.87) 0.001
Any symptomatic DVT 77 (5.4) 101 (7.0) –1.7 (–3.4 to 0.1) 0.75 (0.55 to 1.02) 0.061
Any confirmed PE 42 (2.9) 49 (3.4) –0.5 (–1.8 to 0.8) 0.86 (0.56 to 1.30) 0.463
Any death, DVT or PE 526 (36.6) 626 (43.5) –7.0 (–10.5 to –3.4) 0.74 (0.63 to 0.86) < 0.001
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By 6 months from randomisation, there had been 320 deaths in the IPC group and 361 in the no-IPC
group. The probability of death over the 6 months after randomisation in the two treatment groups is
shown in Figure 6. The Cox model, adjusted for the factors included in our minimisation algorithm,
showed a reduced hazard ratio of 0.86 (95% CI 0.74 to 0.99; p= 0.042) for death up to 6 months after
randomisation in those allocated IPC.
The patients’ OHS scores are shown in Table 14. The numbers of deaths on the OHS were greater than
the number of deaths by 6 months, because some patients died between 6 months and the completion of
their OHS score.
In total, 295 (20.5%) patients in the IPC group had an OHS score of 0–2, compared with 293 (20.4%) in
the no-IPC group, an absolute risk difference of only 0.1% (95% CI –2.8% to 3.1%), a relative risk of 0.98
(95% CI 0.84 to 1.14) and an OR adjusted for baseline imbalance of 0.98 (95% CI 0.80 to 1.19; p= 0.83).
Figure 7 illustrates the differences in functional outcomes in the two treatment groups at the final follow-up.
TABLE 14 Functional status (OHS score) at final follow-up after 6 months
Outcomes IPC, n (%) No IPC, n (%) p-value
OHS score
0 45 (3.1) 45 (3.1) 0.375a
1 94 (6.5) 92 (6.4)
2 156 (10.8) 156 (10.8)
3 306 (21.3) 320 (22.3)
4 181 (12.6) 185 (12.9)
5 309 (21.5) 255 (17.7)
Deadb 330 (22.9) 367 (25.5)
Missing 17 (1.2) 18 (1.3)
a Chi-squared.
b Number of deaths is the number at the time the patients were followed up and is therefore higher than deaths by
6 months (see Table 13).
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We carried out an ordinal analysis of the OHS using ordinal regression (results in Table 15). Neither the
adjusted nor the unadjusted analysis showed a difference in the common odds between those treated
with IPC or standard care.
Table 16 shows the individual dichotomies of the OHS scores. None of the differences between the
treatment groups was statistically significant. However, a post-hoc exploratory analysis of the OHS scores
shows that a 2.6% increase in the proportion of patients surviving at 6 months (p= 0.11) is more than
offset by a 3.8% increase in the proportion of patients surviving with an OHS score of 5 (p= 0.013).
However, this p-value needs to be interpreted with caution given that this analysis was not prespecified,
was exploratory and might be spurious because of this.
TABLE 16 The individual dichotomies of the OHS scores with ORs
OHS score dichotomy No IPC IPC OR 95% CI
0 45 45 1.00 0.70 to 1.64
1–6 1375 1376
0–1 137 139 0.98 0.77 to 1.26
2–6 1283 1282
0–2 293 295 0.99 0.83 to 1.19
3–6 1127 1126
0–3 613 601 1.04 0.89 to 1.20
4–6 807 820
0–4 798 782 1.05 0.90 to 1.22
5–6 622 639
0–5 1053 1091 0.87 0.73 to 1.03
6 367 330
Total 1420 1421 – –
TABLE 15 Summary of ordinal regression analysis of OHS
Comparing standard
care with IPC OR for poor outcome p-value 95% CI lower limit 95% CI upper limit
Adjusted 0.97 0.71 0.86 1.11
Unadjusted 0.98 0.80 0.86 1.12
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Living circumstances at 6 months
There were two questions on the 6-month follow-up form concerning patients’ living circumstances.
Table 17 shows the cross-tabulation of the two variables where follow-up was completed.
To determine if there is a relationship between use of IPC and living circumstances at final follow-up, we
dichotomised the location of the patients at follow-up as living at home (in my own home or in the home
of a relative) or living in an institution/still in hospital (in a nursing home, in a residential home, in-hospital
patient). Those whose living circumstances were classed as ‘other’ or ‘unknown’ were not included in this
analysis. Of those allocated to IPC, 24.7% (266 out of 1076) were living in an institution or were still in
hospital at 6 months, compared with 22.4% (233 out of 806) of those allocated to standard care.
A summary of the logistic regression models is shown in Table 18. In both the unadjusted and adjusted
analysis the CI for the ORs indicate that treatment is not significantly related to location at 6 months in
those who responded at 6 months.
TABLE 18 Summary of logistic regression analysis of living circumstances at 6 months after randomisation
Comparing home with institution at 6 months
(excluding dead and missing)
OR for poor
outcome p-value
95% CI
lower limit
95% CI
upper limit
Adjusted 1.11 0.358 0.89 1.37
Unadjusted 1.14 0.214 0.93 1.39
TABLE 17 Cross-tabulation of responses to questions relating to living circumstances at the 6-month follow-up
Where do you live now?
How do you live now?
Not applicable On my own With partner or relative Missing Total
In a nursing home 120 48 6 171 345
In a residential home 32 34 10 43 119
In my own home 3 413 1101 0 1517
In the home of a relative 0 2 97 0 99
Other 28 5 4 0 37
Unknown 2 0 1 0 3
Missing 0 0 0 36a 36
Total 185 502 1219 250 2156
a Thirty-five of the 36 patients with missing responses to both questions were still in hospital and, therefore, completed
the in-hospital follow-up form.
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Post-phlebitis leg syndrome
The reported frequency of leg swelling and leg ulcers at the 6-month follow-up is shown in Table 19.
However, it is unclear whether or not these reported symptoms indicate the development of post-phlebitis
leg syndrome, or if they simply reflect comorbidities such as heart failure or ulcers due to other causes.
Subgroup analyses
Subgroup analyses were performed to determine if particular types of patients might gain more or less
benefit from IPC. We estimated the effect of treatment allocation on our primary outcome subdivided by
key baseline variables and adjusted for the other factors included in our minimisation algorithm. Subgroup
analyses were performed by observing the change in log-likelihood when the interaction between the
treatment and the subgroup is added into a logistic regression model. We determined whether or not
there was any significant heterogeneity between these subgroups. The lack of any significant interaction
between the subgroups and treatment effect has to be interpreted with caution, given that the trial was
not large enough to identify small to moderate interactions.
Does delay in applying intermittent pneumatic compression impact on
its effectiveness?
There is evidence that DVTs may develop within the first 3 days after a stroke.34 There is often a delay in
presenting with a stroke and there will always be some delay in applying VTE prophylaxis because the
patients need to be assessed and the treatment started. In addition, in a randomised trial there may be
additional delays because of the time taken to obtain consent and enrol the patients. To reduce the
possible impact of this delay, we encouraged collaborators to enrol patients as early as possible after
admission and stipulated that we would ensure that at least 75% of patients are enrolled by day 2, with
day 0 being the day of the stroke.
We hypothesised that IPC would reduce the frequency of our primary outcome to a greater extent among
patients enrolled earlier than among those enrolled later. We therefore examined the effect of treatment
among patients enrolled early compared with those who were enrolled later. We assessed the effect of
delay by applying two different definitions of delay (measured in days from stroke onset to enrolment):
(a) day 0 or 1 versus days 2–7 (the split on which our minimisation algorithm is based)
(b) days 0–2 versus days 3–7 (as stipulated in our sample size estimates).
The results are shown in Table 20 and indicate that, surprisingly, the effect of IPC was not greater in those
in whom it was applied earlier.
TABLE 19 Frequency of reported leg swelling and leg ulcers at the 6-month follow-up
Completed 6-month follow-up form IPC (n= 1098), n (%) No IPC (n= 1058), n (%)
Leg swollen since stroke 388 (35.3) 396 (37.4)
Leg ulcer since stroke 24 (2.2) 19 (1.8)
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Does the severity of stroke impact on the effect of intermittent
pneumatic compression?
Our analyses divided patients into subgroups with different stroke severities including:
l paralysis of leg (able vs. unable to lift the leg) at randomisation
l probability of survival free of dependency (OHS score of < 3) based on the predictive model used
in minimisation.
We hypothesised that those with more severe weakness, or a predicted worse outcome, would have
higher rates of DVT because of more prolonged immobility and the co-occurrence of infections, etc. In
addition, this group may tend to have better adherence to IPC because often they are not so able to
express a wish to have them removed. The results are shown in Table 21 and do not suggest any
significant interaction between these subgroups and the overall treatment effect, although this may reflect
the moderate numbers of patients included in the subgroups as there are marked differences in the effect
sizes in the two subgroups.
TABLE 21 The effect of IPC on primary outcome in subgroups based on severity of leg weakness and
stroke severity
Comparing IPC to no IPC, DVT to no DVT
(dead and missing excluded)
OR for poor
outcome p-value
95% CI
lower limit
95% CI
upper limit
Adjusted: lift both legs – no 0.58 0.164 0.43 0.78
Adjusted: lift both legs – yes 0.84 0.53 1.33
Unadjusted: lift both legs – no 0.59 0.169 0.44 0.79
Unadjusted: lift both legs – yes 0.86 0.54 1.36
Adjusted: probability 0–0.15 0.64 0.793 0.47 0.86
Adjusted: probability 0.16–1 0.68 0.45 1.05
Unadjusted: probability 0–0.15 0.63 0.705 0.46 0.85
Unadjusted: probability 0.16–1 0.70 0.45 1.06
TABLE 20 The effect of IPC based on the delay from stroke onset to randomisation
Comparing IPC with no IPC, DVT with no DVT
(dead and missing excluded)
OR for poor
outcome p-value
95% CI
lower limit
95% CI
upper limit
Adjusted: delay 0 or 1 day 0.71 0.572 0.48 1.04
Adjusted: delay ≥ 2 days 0.61 0.44 0.85
Unadjusted: delay 0 or 1 day 0.69 0.696 0.47 1.02
Unadjusted: delay ≥ 2 days 0.63 0.46 0.87
Adjusted: delay 0–2 days 0.67 0.758 0.50 0.89
Adjusted: delay ≥ 3 days 0.61 0.37 1.01
Unadjusted: delay 0–2 days 0.66 0.839 0.50 0.88
Unadjusted: delay ≥ 3 days 0.63 0.38 1.03
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Is intermittent pneumatic compression more effective in patients at higher
risk of deep vein thrombosis?
It seemed likely that individuals at higher risk of DVT might gain more from IPC than those at lower risk.
In the CLOTS 1 and 2 trials, we showed that immobile stroke patients with the following features had a
greater risk of proximal DVT:3
l dependent in ADL prior to stroke
l prior history of DVT
l unable to lift both arms
l unable to lift both legs.
We undertook subgroup analyses of the effect of allocation to the IPC group on the primary outcome
among individuals with and without at least one of these prognostic factors at baseline. There was no
statistically significant interaction between the baseline risk of DVT and the treatment effect (Table 22),
although this may reflect the moderate numbers of patients included in the subgroups because there are
marked differences in the effect sizes in the two subgroups. The risk of DVT was higher in those with at
least one of the predefined risk factors (13.3%; 257/1927) than in those without (6.7%; 39/585).
Is intermittent pneumatic compression more effective in those patients in
whom anticoagulation is not given or advisable?
In some health systems anticoagulation is used widely for the prophylaxis of DVT in those who have
experienced ischaemic stroke, despite the lack of evidence that this improves overall outcome.12 As a result
of this, IPC and other forms of external compression have often been used in individuals with haemorrhagic
stroke. Therefore, we carried out subgroup analyses among individuals:
l on anticoagulants (as defined in our protocol) versus not, at baseline
l with confirmed haemorrhagic versus ischaemic or unknown pathological type of stroke.
The analyses show (Table 23) that there was no significant interaction between the presence or absence of
these factors at baseline and the treatment effect. The patients who received alteplase, heparin, LMWHs or
oral anticoagulants at baseline had a higher risk of our primary outcome than those who did not [14.9%
(92/619) vs. 10.8% (204/1890)]. However, there was a trend for IPC to have a greater effect in patients
with haemorrhagic stroke, although, overall, the risk of our primary outcome was similar in those with
haemorrhagic and ischaemic stroke [11.8% (38/322) vs. 11.8% (258/2190)]. The lack of a significant
interaction may reflect the moderate numbers of patients included in the subgroups, as there are marked
differences in the effect sizes in the two subgroups.
TABLE 22 The effect of IPC on primary outcome in subgroups based on the presence or absence of at least one risk
factor for DVT
Comparing IPC with no IPC and DVT with no DVT
(dead and missing excluded)
OR for poor
outcome p-value
95% CI
lower limit
95% CI
upper limit
Adjusted: high-risk DVT – no 0.87 0.294 0.45 1.67
Adjusted: high-risk DVT – yes 0.61 0.47 0.80
Unadjusted: high-risk DVT – no 0.89 0.306 0.46 1.71
Unadjusted: high-risk DVT – yes 0.61 0.47 0.80
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Is intermittent pneumatic compression using the Comfort™ sleeves more
effective than that using the standard sleeves?
During the CLOTS 3 trial, it was noted that adherence to IPC was suboptimal. The manufacturer
responded to this information by introducing a modified IPC sleeve, the Comfort™ sleeve, intended to
improve acceptability and thus adherence. We switched to using this new sleeve on 17 October 2011.
Therefore, the first 1679 (59%) patients enrolled in the CLOTS 3 trial were allocated to the original sleeve
or not, and the subsequent patients to Comfort™ sleeve or not. There was little difference in adherence
between the two types of sleeves (see Table 4). We examined the effect on our primary outcome of the
original and the Comfort™ sleeves separately. There was no significant interaction between the sleeve
type and the treatment effect (Table 24).
The results of these subgroup analyses are summarised in the forest plot shown in Figure 8.
TABLE 24 The effect of IPC on the primary outcome in subgroups receiving the Comfort™ sleeves or
standard sleeves
Comparing IPC with no IPC and DVT with no DVT
(dead and missing excluded)
OR for poor
outcome p-value
95% CI
lower limit
95% CI
upper limit
Adjusted: sleeves – Comfort™ 0.59 0.510 0.41 0.87
Adjusted: sleeves – standard 0.70 0.51 0.98
Unadjusted: sleeves – Comfort™ 0.60 0.550 0.41 0.87
Unadjusted: sleeves – standard 0.70 0.50 0.97
TABLE 23 The effect of IPC on the primary outcome in subgroups receiving anticoagulants at baseline and those
with and without intracerebral haemorrhage
Comparing IPC with no IPC and DVT with no DVT
(dead and missing excluded)
OR for poor
outcome p-value
95% CI
lower limit
95% CI
upper limit
Adjusted: anticoagulants – no 0.65 0.897 0.48 0.87
Adjusted: anticoagulants – yes 0.67 0.43 1.06
Unadjusted: anticoagulants – no 0.65 0.870 0.48 0.87
Unadjusted: anticoagulants – yes 0.68 0.43 1.06
Adjusted: haemorrhage – no 0.71 0.057 0.55 0.93
Adjusted: haemorrhage – yes 0.35 0.17 0.75
Unadjusted: haemorrhage – no 0.71 0.071 0.55 0.93
Unadjusted: haemorrhage – yes 0.35 0.17 0.74
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Other prespecified secondary analyses
Intermittent pneumatic compression has usually been used for a relatively short duration in perioperative
patients and those in high-dependency units. In the CLOTS 3 trial, we aimed to maintain the IPC treatment
for up to 30 days, if the patient remained in hospital and was still immobile. However, for a wide variety of
reasons, IPC was often terminated earlier than this or was not applied continuously. In the CLOTS 1 and
2 trials, 79% of proximal DVTs were detected on the first CDU.5 Thus, the risk of DVT seemed to be
highest early on; therefore, any prophylaxis might be more effective during this earlier period when the
risks are highest and the adherence is best. We carried out additional prespecified analyses (including all
those subgroups identified for our primary outcome) of the effect of allocation to IPC on the primary
outcome occurring within 14 days of randomisation, rather than 30 days. This aimed to reduce the impact
of those patients who required IPC for only a few days before becoming mobile or adhered to IPC for only
a short time. In addition, it reflects the practice in many places where acute hospital admissions for stroke
are short and thus prophylaxis is applied only for the first few days.
The number of patients with our primary outcome within 14 days is shown in Table 25. A total of 184
(62%) out of 296 patients with a primary outcome experienced the primary outcome within 14 days of
randomisation. The effect of IPC on the rate of the primary outcome within 14 days is shown in Table 26.
The observed effect size based on the 14-day outcomes was slightly larger (OR 0.58 compared with 0.65)
than that for the 30-day outcomes, but the difference was not statistically significant.
TABLE 26 Effect of IPC on a proximal DVT within 14 days of randomisation
Comparing IPC with no IPC and DVT with no DVT
(dead and missing excluded)
OR for a
proximal DVT p-value
95% CI
lower limit
95% CI
upper limit
Unadjusted 0.58 0.001 0.43 0.80
Adjusted 0.58 0.001 0.43 0.80
TABLE 25 Number of patients with a primary outcome of a DVT occurring within 14 days of randomisation
Outcome
Randomised treatment
IPC, n (%) Standard care, n (%)
Number of patients randomised 1438 (100.00) 1438 (100.00)
Alive no prior DVT 1229 (85.5) 1171 (81.4)
DVT 70 (4.9) 114 (7.9)
Dead without prior DVT 104 (7.2) 122 (8.5)
Missing 35 (2.4) 31 (2.2)
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Chapter 5 The cost-effectiveness of intermittent
pneumatic compression in stroke patients
Introduction
We incorporated a health economic analysis to provide some estimates of the costs of IPC and, therefore,
its cost-effectiveness and cost utility. These data aim to inform decisions about whether or not IPC should
be offered routinely by the NHS.
Methods
We performed a within-trial cost–utility analysis to estimate the cost-effectiveness of IPC with an
intention-to-treat analysis. We measured patient resource use using the duration of stay for the index
stroke following randomisation. Resource consequences included hospital length of stay as well as the
direct costs of IPC capital and equipment. We converted length-of-stay distributions into cost estimates
based on a per-diem hospital cost. Trial centre-/region-specific per-diem hospital costs were based on NHS
Reference Costs in England35 and cost information for NHS Scotland derived from the Scottish Health
Service Costs resource.36 Per-diem hospital costs were derived using 2012/13 tariff information for
Healthcare Resource Group code AA22Z (non-transient stroke or cerebrovascular accident, nervous system
infections or encephalopathy), which is specific for admitted patient care for stroke. The non-elective tariff
spell for hospital reimbursement was £4208 for Healthcare Resource Group code AA22Z up to the
non-elective trim point of 53 days. For length of stay beyond the trim point, a per-diem cost of £210 was
added to the non-elective spell tariff. Conversely, the tariff was reduced by 25% if patient length of stay
was less than 2 days. A per-diem-based cost estimate was used in all economic analyses by calculating the
monetary value of the National Tariff estimates35,36 and national average length of stay for stroke. This
resulted in a per-diem cost of £216. To relax the assumption of a constant rate of activity and use of
hospital resources, a gamma distribution was used in sensitivity analyses to simulate patient cost
distributions as a function of length of stay. Within this scenario, per-diem cost estimates were greater for
initial days in hospital. The results from the sensitivity analysis were quantitatively and qualitatively similar
to the base-case analysis, so are not reported. A NHS hospital perspective was adopted for assessing
resource use and costs. We did not assess the cost of nursing home, social care or the cost of readmissions
to hospital within the first 6 months after randomisation.
Our economic analyses aimed to estimate the costs of preventing a proximal DVT (our primary outcome)
and other adverse outcomes (VTE and deaths). We had originally planned (see protocol) to carry out a
within-trial, short- and long-run cost-effectiveness analysis. However, the short-run analysis demonstrated
that there was little significant difference in hospital costs up to 6 months following randomisation and no
significant difference in the average quality-adjusted survival times, again up to 6 months following
randomisation. We were unable to use these negligible and imprecise estimates of cost-effectiveness as a
foundation for the long-run state-transition modelling that we had originally planned. Unfortunately, the
consent procedures did not include obtaining participant or proxy consent to long-term data linkage which
would provide data on long-term survival and hospital admissions. It is possible that in the future a Caldicott
guardian might provide permission for data linkage. If long-run survival data (up to 5 years) are obtained, we
will be able to calibrate a long-run model of hospital costs and survival and estimate the cost-effectiveness of
using IPC as a means of reducing the risk of proximal DVT in immobilised stroke patients.
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As described in our protocol, we estimated the average (mean) incremental costs and incremental
quality-adjusted survival, expressed as quality-adjusted life-days (QALDs) rather than years. With only a
6-month follow-up and no direct measure of baseline quality of life we were unable to reliably estimate
quality-adjusted life-years.
We estimated the direct cost of preventing VTE events or death in the treatment period with IPC in
immobile stroke patients based on the ARR (see Table 10) and the numbers needed to treat derived from
this. We produced estimates which took into account only the direct cost of providing IPC. We did not
take account of any possible increased hospital costs in the first 30 days associated with IPC use because
these were low and not statistically significant.
We used a standard multiplicative model to estimate QALDs by calculating the area under a linear
interpolation of the EQ-5D-3L index trajectory for each individual using survival times, the EQ-5D-3L utility
index score at 6 months and a modelled baseline EQ-5D-3L utility index score. We used multiple imputation by
chained equations to impute missing health-related quality-of-life data on the EQ-5D-3L questionnaire using
the multiple imputations suite of commands in Stata version 12 (StataCorp LP, College Station, TX, USA).37
The EQ-5D-3L (see Appendix 2) aims to assess patients’ quality of life. In the CLOTS 3 trial, it was measured at
the final follow-up by asking patients or carers to rate them on five domains. Each domain can be scored from
1 (best) to 3 (worst). The EQ-5D-3L score was not collected at the time of randomisation because the validity
of asking patients or carers to rate patients’ quality of life shortly after admission to hospital with a severe
stroke is questionable. We therefore used a Bayesian (belief) network38 to learn the pattern of responses across
the five domains of EQ-5D: mobility (A), self-care (B), usual activities (C), pain or discomfort (D) and anxiety or
depression (E). The pooled 6-month EQ-5D-3L data from the CLOTS 1,8 220 and 3 and FOOD trials39,40 were
used to predict and inform baseline EQ-5D-3L scores for the CLOTS 3 trial patients. Only cases with complete
responses across all five domains were included in the learning algorithm. This resulted in a total sample of
12,282, of which the CLOTS 3 trial contributed 2102 cases. Any EQ-5D-3L responses weighted as zero
resulting from death at 6 months were excluded from the sample because of the explicit assumption that
patients need to be alive at baseline to be randomised.
Bayesian networks are constructed through a two-stage process involving both qualitative and quantitative
components. The qualitative component represents the initial stage and considers the relationship among
key variables to define the structure of the quantitative component. Constraint- and score-based learning
algorithms were evaluated using the bnlearn package in R, version 3.0.1 (The R Foundation for Statistical
Computing, Vienna, Austria). Figure 9 presents the results from the graphical language of the qualitative
component for both types of learning algorithms. Figure 9a represents the constraint-based algorithm based
on a grow–shrink Markov blanket. This naive Bayesian network can be considered one of the simplest
learning algorithm structures. Nonetheless, results were not sensitive to more sophisticated constraint-based
algorithms, such as incremental association classifiers. Instead, the qualitative component was sensitive to the
E
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Constraint-based algorithm(a)
A
B
E
C
D
(b)     Hill-climbing algorithm
A
B
FIGURE 9 Diagram representing (a) the constraint-based algorithm; and (b) the hill-climbing learning algorithm
used to model the EQ-5D-3L scores at baseline for patients in the trial. The arrows indicate a causal relationship in
the hill-climbing algorithm.
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choice between a constraint- and score-based learning algorithm, as depicted in Figure 9b. The score-based
learning algorithm based on a hill-climbing search was selected in favour of the constraint-based approach in
order to account for the dependency between the five domains of EQ-5D. A tree-augmented naive Bayes
network classifier was used to predict and inform baseline EQ-5D-3L scores using a Chow–Liu algorithm to
approximate the dependency structure between the EQ-5D-3L domains.
Mobility (A) is defined as the root node within the hill-climbing algorithm in Figure 9. The consequence of
this categorisation ensures that a particular response to the mobility domain influences responses across
self-care (B), usual activities (C) and pain (D). The graphical language presented in Figure 9 has a causal
interpretation so that a decline in mobility is considered to cause reductions in self-care and usual activities
and worsening of pain. Anxiety/depression, denoted by (E) in Figure 9, represents the leaf node within the
hill-climbing algorithm because of the absence of any causal link from (E) to the other domains of EQ-5D.
Instead, responses for anxiety/depression (E) are considered to be determined by self-care (B), usual
activities (C) and pain (D).
To derive baseline EQ-5D-3L, the score-based learning algorithm was used to predict discrete responses to the
domains of EQ-5D-3L using an informative prior based on expert opinion for the mobility, self-care and usual
activities domains. A prior value of 3 was attached to the mobility domain because the eligibility criteria for
the trial meant that patients had to be immobile on entry. Similarly, we allocated a value of 3 (unable) to
self-care (B) and usual activities (C) given that immobile stroke patients who are in hospital are unable to wash
and dress themselves or carry out their usual activities. The prediction of baseline EQ-5D-3L scores within the
Bayesian network was, therefore, confined to pain (D) and anxiety/depression (E). A sensitivity analysis was
undertaken in which a discrete distribution was also used to simulate responses for the pain and anxiety/
depression domains based on an imputed value of 3 for the other categories. The Bayesian network approach
represents the primary method for estimating baseline EQ-5D-3L scores and the discrete distribution was
explored in sensitivity analyses with results which were both qualitatively and quantitatively similar.
We estimated the direct cost of the intervention to the NHS based on a range of prices provided by
Covidien Ltd, the manufacturer and supplier of the Kendall SCD™ Express devices. Covidien Ltd usually
lends hospitals the controllers (pumps) and tubing, and includes the cost of these in the cost of the
sleeves. The price that the NHS pays for Covidien Ltd’s single-patient use standard and Comfort™ sleeves
depends on the volume purchased and local negotiation. We used a price at the upper end of this range
(£25 per pair), which would subsume the estimated cost of the small amount of time required by nursing
staff to size and fit the sleeves (15 minutes) and to monitor the use of IPC (5 minutes per day). The
per-patient cost of the intervention was based on the average duration of use (about 12 days) and the
average number of pairs of sleeves used by a patient (2.5, range 1–5). The latter was estimated by
subtracting the numbers of sleeves remaining in the centres at the end of the trial (based on a stocktake)
from the total number provided during the trial, divided by the number of patients allocated to the IPC
group. This assumes that the IPC sleeves were used only on patients allocated IPC in the CLOTS 3 trial and
that supplies were not lost by the hospital.
We estimated the average (mean) incremental costs, expressed in 2013 UK pounds, and incremental QALDs.
We also estimated direct costs of preventing VTE events and deaths within 30 days of randomisation.
We used generalised linear models to analyse the distribution of costs and QALDs separately using a general
specification that allowed for different parametric distributions. We also assessed differences in costs and
effects using econometric methods that account for the dependency between each outcome. We used
simultaneous equation individual-level regression models to estimate the joint distribution of costs and QALDs.
We performed non-parametric bootstrapping to assess the joint densities of incremental costs and incremental
effects and to explore uncertainty in the cost-effectiveness results based on 10,000 bootstrap replications
using Stata version 12. All simulations were undertaken within R, version 3.0.1, and exported to Stata,
version 12, for analysis.41 We also performed probabilistic sensitivity analysis to assess the robustness of the
reported results for both short-run QALD estimates and hospital cost distributions. The utilities were based on
published preferences for a UK population.42
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We had planned to estimate the averted costs arising from the effects of IPC on expected DVT/PE
incidence. However, the marginal effect of a change in DVT/PE incidence would be observed only for
symptomatic and treated DVT/PE. These were relatively rare events. We did not see a material difference in
hospital resource use between the treatment groups that could be attributed to a change in DVT/PE
incidence; therefore, we did not enter this into our modelling.
We assessed differences in costs and effects using econometric methods based on a copula framework
that is particularly useful and straightforward when modelling joint parametric distributions. We also
summarised our cost-effectiveness results within a net-benefit approach using incremental net (monetary)
benefit and cost-effectiveness acceptability curves.
Costs and benefits of an effective approach to preventing DVT following stroke will accrue over time.
However, in these analyses we estimated only the short-run costs over the first 6 months
after randomisation.
Results
Costs of intermittent pneumatic compression
The price of sleeves provided by Covidien Ltd was £14 for a medium pair of standard sleeves and £26 to
£31.50 for Comfort™ sleeves depending on size (extra small, small, medium or large). For our analyses we
estimated an average cost of £64.10 per patient, including the cost of sleeves, fitting and monitoring.
We estimated the direct cost of preventing VTE events or death in the treatment period with IPC in
immobile stroke patients (Table 27).
Costs of hospital stay
Table 28 outlines the descriptive statistics for length of stay and the use of IPC sleeves. The average length
of stay for the CLOTS 3 trial sample is substantially higher than the UK national average for stroke,
probably because the patients who were recruited into the trial generally had had more severe strokes.
The UK mean is 19.5 days, with a median of 9 days. A discrete distribution was used to simulate the
number of sleeves used by each patient based around a mean value of 2.5 pairs of sleeves. The discrete
distribution assumed a minimum number of one pair of sleeves, with a maximum number of five pairs.
The cost estimates of IPC and hospitalisation are shown in Table 29.
TABLE 27 Estimates of the direct cost of preventing VTE events or death in the treatment period with IPC in
immobile stroke patients [the CI included ∞ where the 95% CI of the effects (ARR) on that outcome included zero]
Prevention of Cost (£) 95% CI
Proximal DVT (symptomatic or asymptomatic) 1795 1089 to 4551
Any DVT (proximal or distal, symptomatic or asymptomatic) 1282 785 to 3077
Any symptomatic DVT 3546 1923 to ∞
Confirmed PE 16,025 4295 to ∞
Death within 30 days 2756 1346 to ∞
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Health-related quality of life at the 6-month follow-up
We assessed the health-related quality of life at the 6-month follow-up with the EQ-5D-3L. We derived
utilities based on the preferences of a UK population, with values varying from –0.594 to 1.0.42 Figure 10
shows the distribution of EQ-5D-3L scores split by treatment allocation. In these plots, patients who have
died are included with a utility of 0 and those with missing data (IPC, n= 35; no IPC, n= 42) have been
excluded. The descriptive statistics are shown in Table 30, which also shows the results with imputed
outcome data. Given the distribution of the data, we used a two-sample Wilcoxon test to compare the
groups and there is no evidence of a statistically significant difference in the distributions [IPC, median
0.028 (IQR 0.000–0.587); standard care, median 0.024 (IQR 0.000–0.587); p= 0.62].
The effect of treatment on health-related quality of life
We defined effect as the change in utility based on EQ-5D-3L score from baseline (modelled as in Figure 9
and Table 31) to 6 months, divided by 2. We then multiplied this value by survival in days to generate the
QALDs over the 6-month period. We derived the baseline EQ-5D-3L score index from the Bayesian
network rather than the discrete simulation approach (see Table 31). The results are shown in Table 32.
Tables 33 and 34 present the seemingly unrelated regression results for cost and effect. The dependent
variable for the cost equation is cost of sleeves plus hospital days (see Table 29). The standard errors were
derived from bootstrapping based on 10,000 replications in Stata, version 12.1. The results from the
Breusch–Pagan test of independence provide support for the simultaneous estimation of costs and effects.
TABLE 29 Summary of the cost estimates (£)
Costs
IPC (n= 1438) No IPC (n= 1438)
Mean (SD) Median (range) Mean (SD) Median (range)
Cost of IPC 64.10 (28.3) 60.5 (0–159.9) 0.19 (3.8) 0 (0–103.5)
Cost of hospital days 12,503 (8263) 10,283 (1579–43,093) 12,116 (8163) 9694 (1595–43,129)
Cost of IPC plus hospital days 12,567 (8264) 10,338 (1579–43,153) 12,116 (8163) 9694 (1595–43,129)
TABLE 28 Resource use descriptive statistics. Length of stay was truncated at 6 months because some patients were
still in hospital at the 6-month follow-up
Resources
IPC (n= 1438) No IPC (n= 1438)
Mean (SD) Median (range) Mean (SD) Median (range)
Truncated length of stay (days) 44.5 (37.6) 34.0 (1–184) 42.8 (37.2) 32.0 (1–184)
Number of sleeves per patient 2.5 (0.9) 2.5 (1–5) 2.5 (0.9) 3.0 (1–5)
Number of days IPC should
have been worn
22.9 (11.2) 30.0 (0–91) 0 (0) 0 (0)
Number of days actually worn 11.7 (10.6) 8 (0–65) 0.01 (0.3) 0 (0–12)
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FIGURE 10 Distributions of utilities based on EQ-5D-3L and UK population preferences at about 6 months after
randomisation in the IPC and standard care groups. (a) IPC; and (b) standard care.
TABLE 30 Descriptive statistics for the utilities based on the measured EQ-5D-3L and UK population preferences at
about 6 months
Outcome
IPC No IPC
n Mean (SD) Median (range) n Mean (SD) Median (range)
6-month EQ-5D 1403 0.22 (0.39) 0.03 (–0.59 to 1) 1396 0.22 (0.37) 0.02 (–0.59 to 1)
6-month EQ-5D-3L score
multiple imputations
1438 0.23 (0.39) 0.03 (–0.59 to 1) 1438 0.22 (0.38) 0.03 (–0.59 to 1)
TABLE 31 Health-related quality of life at baseline (based on modelling)
Outcome
IPC (n= 1438) No IPC (n= 1438)
Mean
(SD) Median Minimum Maximum
Mean
(SD) Median Minimum Maximum
Baseline EQ-5D-3L
score Bayesian
network
–0.127
(0.13)
–0.095 –0.594 0.028 –0.130
(0.13)
–0.095 –0.594 0.028
Baseline EQ-5D-3L
score discrete
–0.188
(0.17)
–0.166 –0.594 0.028 –0.193
(0.18)
–0.166 –0.594 0.028
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TABLE 32 Overall survival (days) and QALDs at 6 months
Outcome
IPC No IPC
n Mean (SD) Median (range) n Mean (SD) Median (range)
Survival, days
(complete cases)
1403 152.5 (60.6) 183 (0 to 183) 1396 148.1 (64.3) 183 (1 to 183)
Survival, days
(multiple imputations)
1438 153.3 (60.0) 183 (0 to 183) 1438 149.1 (63.6) 183 (1 to 183)
QALDs (complete cases) 1403 27.6 (40.6) 16.6 (–84.3 to 145.9) 1396 26.7 (39.6) 15.4 (–84.3 to 145.9)
QALDs
(multiple imputations)
1438 28.2 (40.7) 17.6 (–84.3 to 145.9) 1438 27.5 (39.8) 15.9 (–84.3 to 145.9)
TABLE 33 Seemingly unrelated regression results for complete cases (n= 2799)
Equation Coefficient Standard error Lower CI Upper CI
Cost equation
Treatment 544.2 303.7 –51.4 1139.4
Constant 12048.0 212.9 11,630.7 12,465.2
Health-related quality-of-life equation
Treatment 0.901 1.52 –2.083 3.885
Constant 26.722 1.05 24.654 28.790
Breusch–Pagan test of independence: χ2= 143.562; p< 0.01.
TABLE 34 Seemingly unrelated regression results for multiple imputed health-related quality of life (n= 2876)
Equation Coefficient Standard error Lower CI Upper CI
Cost equation
Treatment 450.6 306.4 –150.0 1051.1
Constant 12116.3 217.6 11,689.9 12,542.7
Health-related quality-of-life equation
Treatment 0.636 1.49 –2.286 3.558
Constant 27.535 1.04 25.491 29.580
Breusch–Pagan test of independence: χ2= 153.899; p< 0.01.
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Cost-effectiveness analysis (complete cases)
Figure 11 summarises the cost-effectiveness results based on complete cases (n= 2799) based on a
maximum willingness to pay (K) of £1000 per QALD. Essentially, despite the improved survival in the IPC
group there was a gain of less than 1 day in QALDs over the 6-month follow-up period. The incremental
cost-effectiveness ratio indicates that the optimal decision is to select IPC if willingness to pay is greater than
£611 per QALD and the no-IPC treatment pathway if a decision-maker’s willingness to pay is less than
this value.
Figure 12 presents the cost-effectiveness acceptability curve to assess the uncertainty in the cost-effectiveness
results of the cost per QALD. At a maximum willingness to pay of £1000 per QALD, the probability that IPC
is cost-effective relative to standard care is just under 0.6.
The CLOTS 3 trial had more than 90% power to detect an ARR of 4% for proximal DVTs. Although the study
successfully recruited 2876 patients, it was not powered to detect differences in costs or health-related quality
of life, as the required sample size would ensure that the proposed study would be prohibitively expensive.
As a result, decision-making should focus on the additional costs associated with the implementation of IPC
across all net benefits, including the primary clinical outcome of the CLOTS 3 trial. The cost–consequence
analysis should, therefore, consider the budget impact of implementing IPC in routine care rather than
prioritising a ratio measure of a cost per QALD in the light of the trivial changes in QALD reported. This would
ensure that there is a more transparent synthesis of the existing evidence rather than standard threshold
interpretations of ratio measures which are undefined when there is no difference in quality-adjusted survival.
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FIGURE 11 Cost-effectiveness plane. (Incremental cost-effectiveness ratio= 610.88.)
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FIGURE 12 Cost-effectiveness acceptability curve.
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Chapter 6 Discussion
The CLOTS 3 trial has shown that IPC (delivering sequential circumferential compression via thigh-lengthsleeves at a frequency determined by the venous refill time) applied to immobile stroke patients
significantly reduces the risk of proximal DVTs (our primary outcome), symptomatic DVTs (proximal or calf) and
all DVTs (symptomatic or asymptomatic, proximal or calf). We were unable to demonstrate a statistically
significant reduction in PE. Although there was a significant excess of skin breaks and a non-significant excess
of falls with injury, the absolute risks were low and most adverse events were not attributed to the IPC.
The number of deaths within 30 days and within 6 months was lower in the IPC group than in the no-IPC
group, although the differences were not statistically significant. However, our prespecified analysis of
the hazard of death over the first 6 months, adjusted for any baseline imbalance, and which one would
expect to be a more sensitive test of the effect on survival than the dichotomous data and fixed time
points, demonstrated that the relative hazard of death was reduced by about 14% and this was
statistically significant (p= 0.042).
Intermittent pneumatic compression is an inexpensive intervention. The actual cost per pair of Comfort™
sleeves since completion of the trial and implementation of IPC into practice is currently about £20, even
less than the costs we used in the health economic analyses. The cost of preventing DVTs and deaths
appears to be modest, although there are no generally accepted standards to indicate whether or not
these costs represent good value for money. There was no statistically significant difference in the
functional status (OHS score) of patients allocated to IPC or not. However, a post-hoc analysis of the OHS
scores (see Table 13) shows that a 2.6% increase in the proportion of patients surviving at 6 months
(p= 0.11) is more than offset by a 3.8% increase in the proportion of patients surviving with an OHS score
of 5 (p= 0.013), indicating that they are bed bound or chair bound and require all care. This possibly
suggests that many of the deaths which might result from PEs and which can be prevented by IPC occur
in patients with severe strokes and therefore poor functional outcomes. We have previously shown that
dependency in activities of daily living prior to the stroke, greater limb weakness and prior DVT/PE are
independently associated with a greater risk of DVT after stroke3 and, further, that prior dependency and
greater weakness are associated with worse functional outcomes.21 It is therefore not surprising that, if IPC
effectively reduces the risk of DVT and improves survival by preventing fatal VTE, many of the patients who
survive because of IPC will have poor functional status. Patients with poor functional status have a utility,
as determined by the EQ-5D-3L score, which is little different from death. For this reason there is little gain
in quality-adjusted survival.
Perhaps because of the improved survival, the use of IPC was associated with a non-significant increase in
length of stay (mean 1.7 days) and a non-significant increase in NHS hospital costs. Therefore, IPC use is
associated with modest increase in direct hospital-based costs with only a very small gain in QALDs. This
results in an incremental cost-effectiveness ratio of £611 per QALD. However, with a negligible difference
in QALDs, any cost will result in a high incremental cost-effectiveness ratio.
Internal validity
The CLOTS 3 trial protocol was designed to minimise bias and confounding and thus to provide a robust
estimate of the effectiveness of IPC in immobile stroke patients. The CLOTS 3 trial exceeded its recruitment
target and, therefore, had at least 87% power to detect the 3.6% absolute reduction in risk of proximal
DVT observed. The central web-based randomisation system achieved excellent balance for all baseline
characteristics measured and excluded the possibility of any foreknowledge of group allocation which
could have resulted in selection bias.
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The CLOTS 3 trial focused on prevention and identification of proximal DVTs, which are detected more reliably
with CDU and are considered clinically more important than DVTs restricted to the calf.23–25 Calf DVTs are
the most frequent component of the cluster of VTE events used in previous trials of VTE prophylaxis, yet their
detection with CDU is technically challenging and results are inconsistent. The ultrasound technicians and
radiographers were mainly blinded in their assessment of our primary outcome.
We achieved excellent levels of follow-up and we were able to account for all patients at 6 months who
had not withdrawn from the study. All primary analyses kept patients in the treatment group they were
allocated to, irrespective of the treatment they actually received.
Limitations
The trial had some methodological limitations as detailed below.
(a) The primary outcome included asymptomatic DVTs, which are not of huge clinical significance but are
widely used as surrogate outcomes in trials of VTE prophylaxis. Ideally, our trial would have focused on
survival, function and quality of life, although this would have required a much larger sample size.
(b) We included a small number of patients who turned out to have a diagnosis other than stroke. However,
given their small numbers, excluding these patients from the analyses did not alter the conclusions.
(c) Despite only moderate adherence to IPC, the trial demonstrated beneficial effects on VTE and survival.
Data on adherence were sometimes incomplete and not always internally consistent, but it is unlikely
that this would influence our conclusions. We are unable to reliably estimate the effect that imperfect
adherence might have on the observed effect size.
(d) Imperfect blinding of the radiographers could have biased detection of our primary outcome. However,
given that in the majority of cases primary outcomes were confirmed by a blinded central review of
stored images and in the remainder they were confirmed by local clinical reporting by a radiologist,
it seems unlikely that this would have explained the results.
(e) In some cases scheduled CDU did not include the calf veins and some scans were missing. Ideally,
all radiographers would have adhered to a standardised protocol for carrying our CDU which would
have optimised their sensitivity and specificity.
(f) We did not systematically screen for PE with computerised tomography, pulmonary angiography or
ventilation–perfusion isotope scans. It is therefore likely that we underestimated the frequency of VTE.
(g) As we systematically screened for DVT, many patients found to have asymptomatic DVT were then
treated with anticoagulants to reduce the risk of symptomatic events (DVTs, PEs and deaths). This
might bias the estimate of the effect of IPC towards the null.
(h) There was lack of central verification of negative CDU scans. This was not done because it was
impractical and, given the difficulty of interpreting ultrasound retrospectively from recorded images,
we think that it is unlikely that this had an important effect on our results.
(i) There was lack of blinding of nursing staff. It would have been impossible to achieve in practice
because we did not have a practical sham IPC. This might bias nursing staff’s use of background
treatment and assessment of some of the secondary outcomes. However, our data suggest no major
difference in the background treatments that are likely to have resulted in an important bias in favour
of IPC. Although there was an excess of GCS use in the IPC arm, the CLOTS 1 trial showed that GCS
use is not associated with reduced risk of DVT. The lack of blinding of nursing staff may have partly
explained the observed excess of reported skin breaks seen in the IPC group.
(j) There was lack of blinding of patients and their relatives which may have biased their responses to the
OHS and EQ-5D-3L scores at the 6-month follow-up, but it seems unlikely that this would have
affected our conclusions.
(k) A manufacturer of IPC devices was involved in the trial. This might have in theory led to a conflict
of interest among the researchers and distortion of the reporting of the trial results. However, Covidien
Ltd only provided centres with their equipment and had no other role within the trial. They were not
involved in its design, conduct (other than provision of the devices), data collection, storage, analysis or
reporting of the results.
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(I) The economic evaluation is confined to a short time horizon of 6 months and does not include the
costs of readmissions to hospital within the first 6 months after randomisation or include direct
measurement of baseline health-related quality of life. For these reasons, no reliable estimate of
the cost/quality-adjusted life-year could be provided.
External validity
The patients in the CLOTS 3 trial were enrolled by a large number of hospitals in the UK. We did not
require centres to maintain screening logs; therefore, we are unable to report how many patients were
screened for eligibility and what proportion of eligible patients agreed to participate. However, we
purposefully kept our eligibility criteria wide so that the trial would be able to recruit a wide range of
immobile stroke patients who might benefit from IPC. Anecdotally, the main reason for excluding eligible
patients was the limit on the number of CDUs which could be done placed on many of our centres by
their radiology departments.
However, Table 35 compares the characteristics of patients randomised into the CLOTS 3 trial with those
of unselected patients admitted to all 32 Scottish hospitals as acute stroke patients in 2011.43 It also shows
the characteristics of all immobile patients. These data provide a basis for assessing the extent to which
the trial results might apply to future NHS patients in the UK.
TABLE 35 Comparison of the baseline characteristics of patients enrolled into the CLOTS 3 trial (2009–12),
unselected patients with acute stroke and immobile acute stroke patients admitted to Scottish hospitals in 2011
(unpublished data from the Scottish Stroke Care Audit43)
Modelling method CLOTS 3 trial
Unselected stroke
patients in SSCA
Immobile stroke
patients in SSCA
n 2876 10,838 4292
Age (years), mean 74.6 72.4 75.6
Male (%) 48.0 47.2 43.3
Haemorrhagic stroke (%) 13.1 8.5 13.1
Lives alone before stroke (%) 34.9 32.8 38.5
Independent in ADL before stroke (%) 90.3 69.2 67.7
Able to talk and orientated (%) 60.2 60.9 49.1
Able to lift both arms off bed (%) 34.8 59.7 36.0
Unable to walk independently (%) 100 39.6 100
Thrombolysed (%) 17.0 5.8 10.3
Discharged home (%) 48.0 68.5 49.6
Died in hospital (%) 15.6 10.5 19.4
Mean length of stay (days) 43.6 18.0 28.0
Median length of stay (days) 33 6 12
SSCA, Scottish Stroke Care Audit.
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About 40% of acute stroke patients admitted to hospital in Scotland in 2011 were initially immobile and
the vast majority would have been eligible for the trial. It therefore seems reasonable to assume that
IPC would potentially benefit very large numbers of patients each year: perhaps 50,000 in the UK.
However, the in-hospital case fatality of patients enrolled was lower than that of unselected immobile
patients. This reflects that patients were not entered into the trial if they had a very high early risk of
dying, indeed we discouraged enrolment of patients where palliation was the main aim of treatment or
where the patient had a comorbidity which was likely to severely restrict their survival. Patients enrolled in
the trial tended to be more independent before their stroke and to be more often orientated and able to
talk after the stroke. This probably reflects the difficulty of obtaining informed consent from patients who
are unable to communicate or who have cognitive problems. Some research staff were less keen to obtain
consent from proxies even though this was encouraged by our protocol. The much longer lengths of stay
in the CLOTS 3 trial patients probably indicate that research staff preferentially enrolled patients who were
likely, because of their stroke severity, to be immobile for a significant period.
Our subgroup analyses suggest that the effects of IPC on our primary outcome was similar across a broad
range of patients, and was not significantly affected by patient demographics, delays in its application,
stroke severity and background use of antithrombotics. Importantly, IPC appeared to be at least as
effective in patients with haemorrhagic stroke as in those with ischaemic stroke (see Figure 8).
Although adherence to IPC was only modest within the trial, one could speculate whether or not this
might differ from routine practice. In the trial, patients were explicitly told that there was no definite
evidence that IPC would benefit them and also that they could remove the devices without giving a
reason. IPC was a novel intervention for most of the nursing staff caring for patients, and nurses were also
aware that the IPC was being tested, and that it was not of proven benefit. If IPC were to be introduced
into routine practice, staff and patients could be told that it would definitely reduce the risk of DVT and
would probably increase their chances of surviving. This might encourage better adherence than in the
trial. However, we do not know the extent to which patients, their families and nursing staff encouraged
adherence in the trial citing the potential benefits for the trial and future patients with stroke.
The IPC devices used in the trial were provided by one manufacturer. IPC devices vary in their characteristics,
for example in the length of the sleeves (calf only or thigh length), the frequency of compression, whether
inflation is rapid or gradual, sequential (distal before proximal) or single (distal and proximal at the same
time), and whether compression is circumferential or applied to only the back of the calf. It is unclear if
other types of IPC device in widespread use in the UK would achieve greater, lesser or the same effects as
those observed in the CLOTS 3 trial.
Putting the results in context
The CLOTS 3 trial aimed to establish whether or not IPC reduces the risk of DVT in patients who are initially
immobile after being admitted to hospital with an acute stroke. Prior to starting the trial, we searched for
other trials which had addressed this question in stroke patients. We updated this search in March 2013.
We searched the Cochrane Stroke Group Trials Register, the Cochrane Central Register of Controlled Trials,
MEDLINE (1966 to March 2013), EMBASE (1980 to March 2013), the Cumulative Index to Nursing and
Allied Health Literature (CINAHL; 1982 to March 2013) and the British Nursing Index (1985 to March 2013)
using the search terms listed in Appendix 4. We screened reference lists of all relevant papers, searched
ongoing trials registers (March 2013) and contacted experts in the field. We included unconfounded RCTs
comparing IPC for reducing the risk of DVT with a control and in which trial treatment was started within
7 days of the onset of stroke. In late 2014, the National Institute for Health and Care Excellence completed
a systematic review of the evidence of IPC in stroke patients and did not identify any additional
randomised trials.
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Only the two small RCTs included in the original review were identified.44,45 When the results of the CLOTS
3 trial are incorporated, the estimates of treatment effects are an OR of 0.66 (95% CI 0.52 to 0.84) for
proximal DVT, an OR of 0.71 (95% CI 0.59 to 0.85) for any DVT and an OR of 0.81 (95% CI 0.65 to 1.01)
for deaths by the end of the treatment period. The two other trials did not report any symptomatic DVTs
or PEs.44,45
The reduction in DVT observed in the CLOTS 3 trial is likely to be because of the reduced venous stasis
and possibly the effects on intrinsic fibrinolysis observed with IPC.18 The improved survival to 6 months
observed in those allocated to IPC is potentially of clinical significance. Unfortunately, the autopsy rate was
very low; therefore, we were unable to reliably assign a cause to most deaths, especially given the difficulty
of distinguishing PE from other cardiorespiratory problems in stroke patients.9 There was an intriguingly
lower frequency of deaths due to pneumonia in the IPC group. Therefore, taken with the pattern of
benefits across all the secondary outcomes, it seems plausible that the difference in survival may be real
and attributable, at least in part, to IPC. The most probable mechanism is a reduction in undiagnosed PE
which contributed to death.
Previous meta-analyses of trials of heparins/LMWHs in stroke patients have demonstrated significant
reductions in PE (3 out of 1000, 95% CI 1 to 3) but only a non-significant reduction in deaths (9 out of
1000, 95% CI –29 to 18), perhaps in part because any reduction in major VTE was offset by a significant
increase in major bleeds (6 out of 1000, 95% CI 2 to 12).12 In contrast, IPC was not associated with an
excess of any major adverse effects that might offset the benefits. The observed effect of IPC on survival
in the CLOTS 3 trial is also reassuring about its safety in this high-risk vulnerable population.
The CLOTS 3 trial has shown that application of IPC to the legs of patients admitted to hospital with stroke
who are initially immobile reduces their risk of DVT, and also appears to increase their chances of surviving
to 6 months. However, similar to other interventions which aim to prevent or treat complications after
stroke (e.g. tube feeding,40 antibiotics46), IPC does not appear to improve the functional outcomes
of survivors.
The results of the CLOTS 3 trial have already been widely disseminated.33,47 IPC is relatively inexpensive
and is already being widely implemented in stroke units in the UK.47,48 The national audits of stroke care
patients in Scotland (Scottish Stroke Care Audit43) and the rest of the UK (Sentinel Stroke National Audit
Programme49) have been monitoring the use of IPC in stroke patients prospectively since January 2014
to determine the speed of implementation.
DOI: 10.3310/hta19760 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 76
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53

Chapter 7 Conclusions
Guidelines
The National Institute for Health and Care Excellence, Scottish Intercollegiate Guidelines Network, the
European Stroke Organisation and the Danish Stroke Society have all taken account of the CLOTS 3 results
and recommend that IPC should be considered for VTE prophylaxis after stroke. Other guidelines groups
are updating their recommendations to take account of these data. If guidelines recommend the use of
IPC in immobile stroke patients admitted to hospitals this will have important implications for health care
and raise important questions for service providers.
Implications for health-care providers
How to train the staff to implement the guideline recommending
intermittent pneumatic compression use in stroke patients?
Medical, nursing and therapy staff working in UK stroke units, and those in many other parts of the world,
have little experience of applying IPC to their patients. They require training in:
l selecting appropriate patients who might benefit
l providing information about IPC to the patients and/or their carers
l sizing the sleeves
l fitting the sleeves
l monitoring their use, including being alert to complications
l dealing with technical problems, for example high- and low-pressure alarms.
Manufacturers of IPC devices do provide some training in the use of their products, but this rarely keeps
up with the turnover in staff. As a minimum, all staff coming into contact with patients receiving IPC
(e.g. physiotherapists or care assistants) will need to know how to switch the systems on and off and how
to reapply the sleeves. Online training is now freely available at www.stroketraining.org.
Further research questions
Should intermittent pneumatic compression be used in a broader group of
medical patients?
Given the demonstrated effectiveness of IPC in surgical19 and stroke patients, it seems very likely that
it would also reduce the risk of VTE in other groups of medical patients at high risk of VTE. Those
responsible for writing national guidelines might extrapolate from surgery and stroke to medical patients.
However, if they do not consider this appropriate, IPC should probably be tested in high-risk medical
patients. The even more important question is whether or not it would significantly improve survival in this
huge group of patients, which is estimated to be 750,000 per year in the UK alone.50 However, given the
uncertainty about the effect of prophylactic anticoagulation with heparin in medical patients on survival,
there is a case for a very large factorial design trial testing both anticoagulants and IPC with survival as
the primary outcome. This would be practical only if an effect size of perhaps 10 deaths avoided per
thousand patients treated were considered the minimal clinically important difference. Preliminary studies
of the size of the benefit which would be considered worthwhile by patients, carers, clinicians and
commissioners and a value of information modelling exercise could further guide whether or not such
very large trials are a sufficiently high research priority for the NHS.
DOI: 10.3310/hta19760 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 76
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
Can adherence to intermittent pneumatic compression be improved,
which in turn might increase its effect?
In trial conditions, adherence to IPC was modest and it is likely that this reduced the size of the effect
observed. Research into methods to improve adherence to IPC might provide information which would
increase the benefits of IPC in stroke patients.
CONCLUSIONS
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Writing group
M Dennis (chairperson), P Sandercock, C Graham, J Smith and J Forbes.
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Chief Scientist Office, Scotland: M Dennis, P Sandercock, J Reid and S Lewis.
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Updating systematic review of randomised controlled trials of
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Norfolk and Norwich University Hospital (15): A Metcalf, S Anderson, N Gange, J Jagger, P Myint, J Potter,
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Watford General Hospital (10): D Collas, T Attygalle, P Botten, K Butchard, M Caton, S Daniels, A Divers,
M Hoare, P Jacob, C Merrill, J Napper, S Sarin, A Sinclair, S Sundayi and E Walker.
Fairfield General Hospital (9): K Kawafi, S Bhat, L Harrison, L Johnson, R Namushi, A Picton and L Smith.
Darlington Memorial Hospital (9): B Esisi, V Baliga, E Brown, J Kent, C McGrath and A Mehrzad.
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Solihull Hospital, Heart of England NHS Trust (8): K Elfandi, A Britton, Gregory, U Khan, R Morris,
M Sandler and K Warren.
Royal Lancaster Infirmary (8): P Kumar, C Culmsee, M Schofield and S Timperley.
Victoria Hospital (8): N Chapman, V Cvoro, K McBride, K McCormick and S Pound.
Monklands Hospital (7): M Barber, D Esson, J Guse, C Maguire and A Talbot.
Darent Valley Hospital, Dartford and Gravesham NHS Trust (7): P Aghoram, A Anstead, T Daniel, S Hussein
and P Mellor.
Princess Royal University Hospital (7): B Piechowski-Jozwiak, D Bettesworth, D Jayasinghe, E Khoromana,
R Lewis, D Ramsey and K Rhodes.
Chesterfield Royal Hospital (6): M Sajid, M Ball, M Beardshall, S Glenn, A Rashid and S Southern.
East Surrey Hospital (5): Y Abouslieman, S Collins, A Jolly, M Mabbutti, M McDade and N Powell.
Frimley Park Hospital (5): O Speirs, S Atkinson, B Clarke, Manock, L Moore and P Ramsey.
Kent and Canterbury Hospital (4): H Baht, I Burger, J Burt, L Cowie, Nair, F Smith and A Thomson.
Medway Maritime Hospital (4): S Sanmuganathan, P Akhurst, S Burrows, T France, M Mamun and
F Williams.
Southport District General Hospital (3): P McDonald, J Horsley, J Murray, H Terrett and S Wareing.
University Hospital of South Manchester NHS Foundation Trust (3): E Gamble, K Keating, S Mawn,
K Norse, P O’Neill and R Pole.
Ninewells Hospital and Medical School (3): R MacWalter, A Doney, N Duffy, A Kelly, S Pillai and M Stirling.
Borders General Hospital (2): S Kerr, A Brown, S Haines, M Mackay and J Reid.
Hull Royal Infirmary (2): A Abdul-Hamid, R Conet-Baldwin, J Greig, K Mitchelson, P Parker, R Rayessa and
L Sunman.
Royal London Hospital (2): P Gompertz, P Daboo, M Farrugia, E Friedman, J Richards, K Saastamoinen,
A Salek-Haddadi and R Yadava.
Cumberland Infirmary (2): P Davies, Z Ferguson, C Hagon and S Holliday.
Royal Albert Edward Infirmary (2): A Suman, P Farren and U Skulbedau.
Scunthorpe General Hospital (2): A Banerjee, D Briggs, B Evans, K Kent, N Nadeem and K Short.
University Hospital of Hartlepool (1): D Bruce, O Bowman, B Kumar and M Platton.
Kings Mill Hospital (1): M Cooper, J Burkitt, L Cordon, A Feely, K Hannah, P Hill, M Nasar, A Rajapakse
and I Wynter.
Diana Princess of Wales Hospital (1): J Adiotomre, A Ali, D Briggs, K Short, J Wallhead and J Wivell.
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Follow-up centres
Bexhill Hospital: C Athulathmudali, M Barbon, S Holmes, A Mason and C Parter.
Chelsea and Westminster Hospital: M Pelly, E Beranova, H Lee, H Reid and T Sachs.
Lymington New Forest Hospital: G Durward, S Evans, W Foster, M Harris and V Pressly.
Newham General Hospital: P Gompertz, P Daboo, M Farrugia, A Jackson, J Richardson and H Syed.
Pontefract Hospital: A Keeney, R Barr, G Bateman, MA Carpenter, R Davey, T Hendra, A Needle,
A McGuinness and Stanners.
St Bartholomews Hospital, Rochester: T France, P Akhurst, S Burrows and F Williams.
West Middlesex University Hospital NHS Trust: R Singh, J Platt, M Teklay and S Wakely.
Whipps Cross University Hospital: R Yadav, E Clough, D Maguire, P Purdy and R Simister.
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Appendix 2 Data collection forms
          CLOTS 3/RF/V2(17/01/10) 
  
 
To randomise: WEB www.clotstrial.com OR PHONE XXX XXXX XXXX 
Please ensure you have supplies of appropriate sleeves too! 
 
CENTRE DETAILS 
Country:  ___________________________ or code  
Centre name:  ___________________________ or code  
Responsible consultant: _____________________ or code  
 
Randomising person: ____________________________  
 
Has consent been given?   (Key 1)  (must be yes) 
 
Patient’ s Family name:_____________________ Given name:____________________________ 
Date of birth / /   (dd/mm/yyyy) Sex: Male  (Key 1)  Female  (Key 2) 
Date of stroke onset / /  (dd/mm/yyyy) 
Date of admission / /  (dd/mm/yyyy)     
            Yes (Key 1) No (Key 0) Unknown (Key 9) 
1. Did the patient live alone before admission?        
2. Was the patient independent in everyday activities before this stroke?     
 (i.e. walking, dressing, feeding, toileting & washing) 
The patient:  
3.  Is able to walk without the help of another person?      
4. Is able to talk and orientated in time, place and person?      
5. Is able to lift both their arms off the bed?        
6. Is able to lift right leg off the bed?       
7. Has a flicker of movement or better in the right leg?      
8. Is able to lift left leg off the bed?          
9. Has a flicker of movement or better in the left leg?      
10. Is overweight?           
11. Is known to be diabetic?          
12. Is known to have symptoms or signs of peripheral vascular disease?    
13. Is known to be a current smoker?        
14. Is known to have a history of previous DVT or PE?       
15. Has taken aspirin, dipyridamole (Persantin), or clopidogrel (Plavix) in last 24hrs?    
16. Has been given rt-PA since admission?        
17. Is on heparin or LMWH now?         
18. Is on oral anticoagulants e.g. warfarin now?       
19.  Do you think it will be practical / possible to perform a second Doppler    
 in 25 to 30 days time (in addition to one between Day 7 and 10)?  
 
Treatment Allocation (please tick the appropriate box)   CLOTS Patient ID ___________________  
Apply intermittent compression sleeves   Avoid sleeves until discharge    
• Sleeves, if allocated, should be worn whilst in bed or chair and until independently mobile or discharged home.  
• Record the allocation on this form, in the medical notes and on the drug chart.  
• Inform all the relevant people about the allocation then file this form in the patient’s medical notes.  
• Book the Doppler ultrasounds now so they will be done on Day 7-10 and Day 25-30. 
Thank you for randomising this patient. 
CLOTS 3 - Randomisation Form 
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          CLOTS 3/RRF/V1(11/07/08) 
CLOTS 3 - Radiology Report Form  
 
Enter online at www.clotstrial.com or return by fax XXX XXXX XXXX 
 
Hospital Number:          or Hospital Name:     ______________________________________ 
 
 
Patient ID:  _____________  Patient Initials:  ___________   Date of Birth:        _____ / _____ / ______ 
 
 
Procedure performed today  Doppler    Venography   Both  
 
 
Date(s) procedure performed   Doppler  ____/____/____ Venography ____/____/____ 
 
 
Did this patient attend wearing compression sleeves? Yes  No  
 
 
Results -  Any D.V.T. present? Yes  No  
 
If any DVT present please send best still picture that demonstrates this to the CLOTS 
Co-ordinating Centre (address below). 
 
If  Yes: 
        Right Leg Left Leg 
Femoral:  Yes,  definite       
   Yes,  probable      
   None        
Popliteal:  Yes, definite       
Yes, probable       
   None        
Calf:   Yes, definite       
Yes, probable       
None        
          Veins Not Visualised/Examined    
 
 
We need to know if you are aware of whether the patient has been wearing compression sleeves – this will tell 
us how “blind” you are to the treatment allocation  
 
Do you think this patient has been wearing compression sleeves (Do not ask the patient!)?     
   Yes            No         No Idea   
 
Procedure performed by: Name of person doing scan ____________________________  
Radiologist   
Sonographer   
Technician   
Doctor    
Other – please specify _______________________________________ 
 
Name of person completing form _________________Signature____________Date: ____/____/____ 
                            day   month   year 
 
Enter online at www.clotstrial.com or return by fax XXX XXXX XXXX 
 
 
 
          CLOTS 3/DF/V3(17/01/10) 
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HOSPITAL & PATIENT ID 
 
Hospital Number OR Name:  __________________________________ 
 
Patient Identifiers: CLOTS ID: ________  Patient Initial:  __________    
 
ABOUT THE STROKE 
  
Was stroke the final diagnosis in this patient? Yes   No     
(a normal brain scan is compatible with a diagnosis of stroke) 
If not a stroke, please specify the diagnosis:_______________________________________   
                              For office use 
  
Was the stroke due to:  cerebral infarction?  haemorrhage?  uncertain?  
 
 
DRUGS DURING HOSPITAL STAY 
 
 
Has this patient taken any of the following drugs since randomisation (Tick all appropriate)?   
Aspirin   Dipyridamole (Persantin)   Clopidogrel (Plavix)  Other antiplatelet   
 
Prophylactic dose heparin/LMWH   Treatment dose heparin /LMWH  
 
Warfarin  Other oral anticoagulant   None  
 
 
If patient was given heparin, LMWH or warfarin during admission please give reasons: 
 
To prevent stroke      To prevent DVT or PE  
Artificial heart valve     To treat DVT or PE   
Atrial fibrillation (AF)   
 
Other   Please specify ______________________________________________________   
           For office use  
 
 
Has the patient worn Graduated Compression Stockings during this admission? Yes  No  
 
If yes, which length were worn? Long only    Short only    Both   
 
USE OF COMPRESSION SLEEVES  
Since randomisation, has this patient  
 
Worn thigh- length Compression Sleeves at any time?  Yes   No  
 
        If yes on which leg(s)? Right        Left   
 
 
 
If the allocated use of compression sleeves has not been followed, please give reasons below: 
 
___________________________________________________________________________   
                                                        For office use 
                                                                                                                              CLOTS3/DF/V3(17/01/10) 
If wore compression sleeves at any time since randomisation  
 
Date sleeves first worn  ___/____/____ Date sleeves last worn ____/____/____ 
 
Please complete this form on the patient’s discharge from hospital, transfer from the centre or 
death (whichever occurs first) as accurately as possible. 
 
CLOTS 3 - Discharge Form 
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Number of days (between these dates) sleeves not worn _____________  
  
If compression sleeves were taken off please tick one reason below: 
 
Patient had 2nd Doppler after 30 days    Patient refused to wear sleeves       
Patient completed 30 days of IPC     Patient complained of discomfort       
Patient independently mobile     Concerns about skin condition on legs    
Other difficulties encountered     Please specify__________________________  
                                      For office use  
Please describe any skin problem on leg? ____________________________________________  
  
Did the skin problem resolve after removal of the IPC? __________________________________  
                                      For office use  
 
 
 
MAJOR EVENTS SINCE RANDOMISATION 
 
Symptomatic or clinically apparent DVT?  Yes  No  
(not clinically silent DVT diagnosed on screening Doppler)   
        If yes give date 1st diagnosed  __/ /___ 
 
Pulmonary Embolism?     Yes  No  
 
        If yes give date 1st diagnosed ____/____/__ 
  
Skin break on either leg?    Yes   No   
(within 30 days of enrolment) 
        If yes give date 1st diagnosed _ __/____/__ 
 
Fall resulting in injury?    Yes   No   
(within 30 days of enrolment) 
 
        If yes give date 1st diagnosed  __/ _/___ 
 
 
DETAILS ~ SYMPTOMATIC DVT 
 
Were the symptoms of a DVT recognised before the Doppler ultrasound?   Yes  No  
 
If Symptomatic DVT diagnosed how was it confirmed?  
 
Doppler ultrasound  Venography  Other  Please Specify _________________  
             For office use  
Please specify the location(s) of any symptomatic DVT(s)  
 
Right leg  Calf    Popliteal   Femoral   
 
Left leg  Calf    Popliteal   Femoral  
 
DETAILS ~ PULMONARY EMBOLISM  
If Pulmonary embolism diagnosed how was this confirmed? 
 
V/Q Scan   CT Angiography   Other  Please Specify _________________  
             For office use 
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
CLOTS 3/DF/V3(17/01/10) 
DETAILS ~ SKIN BREAKS ON LEGS 
 
Was patient wearing compression sleeves when developed skin break?    Yes  No  Unsure   
 
Do you think the skin break was caused by the IPC sleeves or tubing Yes  No  Unsure   
 
Did the skin break heal before discharge?      Yes  No  Unsure   
 
Did the skin break require any operative treatment (e.g. amputation) Yes  No  Unsure   
_____________________________________________________________________________________________ 
 
DETAILS ~FALLS RESULTING IN INJURY  
Was the patient wearing compression sleeves at the time of the fall(s)?Yes    No    Unsure   
 
Do you think the fall was caused by the IPC sleeves or tubing?  Yes    No    Unsure   
 
Did the patient sustain a fracture?      Yes    No  
 
Please provide details of injury due to fall below 
_______________________________________________________________________________________  
            For office use 
SURVIVAL & DISCHARGE 
 
Did the patient survive to discharge from the randomising centre? 
 
Yes   No   
 
     
    If No, date of death (dd/mm/yyyy) ____/____/___ 
 
 Primary cause of death (please tick one box only) 
 
  Neurological damage from initial stroke (e.g. coning)  Pneumonia 
 
    Pulmonary Embolism   Recurrent stroke Coronary heart disease 
 
  Other vascular, please specify:_____________________________________  
 
  Non-vascular, please specify ______________________________________  
_ 
  Due to compression sleeves, please specify:__________________________  
 
  Uncertain, please specify: _________________________________________  
            For office use 
  
Cause of death confirmed by autopsy? Yes  No  
 
    If Yes, date of discharge (dd/mm/yyyy)     
    ____/____/____ 
 
Has the patient been discharged to: (tick one box only) 
 
  Own home, alone  At home, with partner or relative 
 
  Relative’s home    Residential home 
 
  Long term care/nursing home 
 
  In hospital rehabilitation  
 
  Other, please specify ___________________________________________   
                          For office use  
 
Was this patient independently mobile on discharge? Yes  No  
CLOTS 3/DF/V3(17/01/10) 
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CONTACT DETAILS: 
 
 
Patient’s full postal address on discharge _________________________________________________ 
Post Code: ___________________Telephone:____________ 
 
AND 
 
Family Doctor’s Name:____________________ 
Full postal address:_____________________________________________ 
Postcode:_______________Telephone:________________ 
 
Please provide contact details of other persons (e.g. daughter or son) who does not live with patient: 
Name: _____________________________ 
Relationship:_____________________________________ 
 
Full postal address:________________________________________________ 
Postcode:___________________Telephone:_______________ 
 
AND ANOTHER  
Name: _____________________________ 
Relationship:_____________________________________ 
 
Full postal address:_______________________________________________ 
Postcode:___________________Telephone:_____________ 
 
ADDITIONAL INFORMATION 
 
(Please use this space below for any additional information you may think relevant to the trial or to the 
patient’s treatment) 
 
___________________________________________________________________ 
 
    
For office use 
 
Name of person completing form _______________________________________________________ 
 
Signature __________________________________________________   
 
 
Date:  ____/____/____ 
day  month  year  
 
Enter online at www.clotstrial.com or fax back on XXX XXXX XXXX 
CLOTS  
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3/GPQ/V1(11/07/08) 
 
  
CLOTS – 3  GP Questionnaire 
 
 
 
 
Patients Name:  <<Patient name >> 
 
Date of Birth:   << Date of Birth >> 
 
 
Is this patient alive? Yes    No 
 
If patient is still alive, please confirm that the following contact details are correct and amend if necessary  
 
<< address >>  <<Tel No.>> 
 
Has the patient had any of the following since hospital discharge on <<date of discharge>>? 
 
If yes, what was the date first diagnosed? 
 
Deep Vein Thrombosis?      Yes  No   _   /   _ /___   
 
Pulmonary Embolism?      Yes  No   _   /   _ /___ 
 
Evidence of post-DVT leg syndrome?  Yes   No     _   /   _ /___ 
(i.e.  swelling, pain, new ulcer)    
 
 
If possible, please tell us how any of these diagnoses were confirmed (e.g. venography, VQ scan) 
 
 
 
Is this patient taking warfarin?    Yes  No  
 
Reason why (in particular have they had a DVT or PE)  
 
 
If this patient has died, please confirm the date and cause 
 
Date of death   _   /   _ /___ 
 
Cause of death.        _____________________________________________________________  
 
Was cause of death confirmed by autopsy?   Yes  No  
 
 
Name of person completing form _________________Signature____________Date: ____/____/____ 
                           day  month year   
Thank you very much for your assistance. 
Now please fax this form to us at XXX XXXX XXXX or send to:  
The CLOTS Trial Co-ordinating Centre,  
Bramwell Dott Building, Western General Hospital, Crewe Road, Edinburgh UK EH4 2XU 
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         CLOTS 3/FUF/V1(11/07/08) 
  
CLOTS - Follow-up Questionnaire 
 
 
Dear <<patients name>> please answer the following questions: 
 
Please tick one box on each line 
 YES   NO 
Has the stroke left you with any problems?  
 
 
 
Do you need help from anybody with everyday activities? 
 
 
    
How do you live now?  (please tick one box only) 
On my own  
 
With my partner or  relatives 
  
 
Where do you live now?  (please tick one box only) 
In my own home 
 
In the home of a relative 
 
In a residential home 
 
In a nursing home 
 
YOUR TABLETS 
 
Are you currently taking (please tick appropriate boxes)?  
            
Aspirin 
 
Dipyridamole (Persantin) 
 
Clopidogrel (Plavix) 
 
Warfarin 
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PROBLEM WITH YOUR LEGS? 
 
 
YOUR RIGHT LEG 
 
 
 Yes No 
Since discharge from hospital have you had a clot in this leg 
(deep vein thrombosis, DVT)?   
Do you suffer from a swollen ankle or leg? 
  
Have you had a leg ulcer since your stroke? 
  
YOUR LEFT LEG 
 Yes No 
Since discharge from hospital have you had a clot in this leg 
(deep vein thrombosis, DVT) ? 
 
  
Do you suffer from a swollen ankle or leg? 
  
 
Have you had a leg ulcer since your stroke? 
  
YOUR LUNGS 
 Yes No 
Since discharge from hospital, have you had a clot  
in your lungs (pulmonary embolus, PE)?   
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Tick ONE box next to the sentence which best describes your present 
state. 
 
 
 
 I have no symptoms at all 
 
 I have a few symptoms but these do not interfere with 
my everyday life 
 
 I have symptoms which have caused some changes in 
my life but I am still able to look after myself 
 
 I have symptoms which have significantly changed my 
life and I need some help in looking after myself 
 
 
 I have quite severe symptoms which mean I need to 
have help from other people but I am not so bad as to 
need attention day and night 
 
 I have major symptoms which severely handicap me 
and I need constant attention day and night 
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YOUR GENERAL HEALTH 
 
By placing a tick in one box in each group below, please indicate which 
statements best describe your own health state today. 
 
Mobility 
I have no problems in walking about     
I have some problems in walking about     
I am confined to bed/ chair       
 
Self-Care 
I have no problems with self care      
I have some problems with washing or dressing myself  
I am unable to wash or dress myself     
 
Usual Activities 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities    
 
Pain/discomfort 
I have no pain or discomfort       
I have moderate pain or discomfort     
I have extreme pain or discomfort      
 
Anxiety/depression 
I am not anxious or depressed      
I am moderately anxious or depressed     
I am extremely anxious or depressed     
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Did you complete this form yourself?   
 
 
 
 Yes  
 
 No, it was completed by a relative or friend  
 
 
 
Date of form completion  _____(day) _____ (month) ____(year) 
 
 
 
We usually tell your GP how you are getting on based on your answers to our 
questions. Please tick this box if you would prefer us not to tell your GP   
 
 
 
 
 
Thank you very much for taking the time to complete this form 
 
Please return it using the pre-paid envelope provided 
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Appendix 3 Close out checklist
CENTRE CLOSE OUT FORM & ARCHIVE CHECKLIST
FOR CLOTS 3 CENTRES
CENTRE DETAILS
Centre Number / Name
Principal Investigator (PI) 
Hospital Co-ordinator (HC)
Number of patients recruited
All data in and verified YES, Thank you!
I CAN CONFIRM THAT:
Please tick
1. ESSENTIAL 
DOCUMENTATION
· all documents that were needed for the site set up are in the Site File 
(any approvals, etc are available via CSP)
· the PI has signed that the site file is complete
· copies of site specific patient informed consent forms are present
2. AUDIT AND 
INSPECTIONS
· the local study team is aware that inspections and audits may 
still be carried 
out after the end of the trial
3. DELEGATION LOG TASKS
· final dates to be added for each researcher
· log signed and dated as closed by the PI
4. COLLECTION OF PUMPS AND SLEEVES
· pumps have been returned to Covidien using the freepost labels provided
· full boxes of sleeves have been returned to Covidien using the freepost labels 
provided
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5. ACKNOWLEDGMENTS 
Centres who have randomised one or more patients (see page 1 for 
recruitment at your   centre) will be acknowledged in all future publications 
(as per protocol).  
• acknowledgements have been completed via the CLOTS website 
6. ARCHIVING
• our local R&D department has been notified to the close out of CLOTS 3
at our 
site
• all relevant information relating to CLOTS 3 patients recruited at our site has
been filed as per our Trust’s policy on archiving
Signature of Principal Investigator: _________________________________
Date: _________________________________
Please return to the CLOTS Trial Co-ordinating Centre
by email (XXXX) or fax on (XXXX XXX XXXX)
Thank you for supporting the CLOTS 3 Trial
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Appendix 4 Search strategies used
MEDLINE (via Ovid)
We used the following search strategy for MEDLINE (via Ovid) and adapted it to search the Cochrane
Central Register of Controlled Trials:
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp
carotid artery diseases/ or exp intracranial arterial diseases/ or exp “intracranial embolism and
thrombosis”/ or exp intracranial hemorrhages/ or stroke/ or exp brain infarction/ or vasospasm,
intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$
or emboli$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or subarachnoid) adj5 (haemorrhage$ or
hemorrhage$ or haematoma$ or hematoma$ or bleed$)).tw.
5. 1 or 2 or 3 or 4
6. thrombosis/
7. thromboembolism/
8. venous thrombosis/ or venous thromboembolism/
9. thrombophlebitis/
10. deep venous thrombo$.tw.
11. deep vein thrombo$.tw.
12. ((venous or vein) adj5 thrombo$).tw.
13. (DVT or VTE).tw.
14. thromboprophylaxis.tw.
15. phlebothrombosis.tw.
16. exp pulmonary embolism/
17. pulmonary artery/ and embolism/
18. ((pulmonary or lung) adj5 (embol$ or thrombo$ or infarct$)).tw.
19. or/6-18
20. Intermittent Pneumatic Compression Devices/
21. bandages/ or stockings, compression/ or gravity suits/
22. (pneumatic adj5 (compression or device$ or appliance$ or stocking$ or hose or boot$ or suit
or suits)).tw.
23. ((pneumatic or electric$ or compression) adj5 pump$).tw.
24. (intermittent adj5 (compression or impulse device$)).tw.
25. (compression adj5 (device$ or system$ or stocking$ or hose or boot$)).tw.
26. ((elastic or antiembolic or anti-embolic) adj5 (stocking$ or hose)).tw.
27. (mechanical adj5 (prophylaxis or compression)).tw.
28. (inflatable adj5 (device$ or garment$ or stocking$ or hose or boot$)).tw.
29. IPC.tw.
30. (sequential adj5 compression).tw.
31. exp Electric Stimulation/
32. exp Electric Stimulation Therapy/
33. (electric$ adj10 stimulat$).tw.
34. electrostimulation.tw.
35. or/20-34
36. 5 and 19 and 35
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EMBASE (via Ovid)
We used the following search strategy to search EMBASE (via Ovid):
1. cerebrovascular disease/ or basal ganglion hemorrhage/ or cerebral artery disease/ or cerebrovascular
accident/ or stroke/ or exp carotid artery disease/ or exp brain hematoma/ or exp brain hemorrhage/ or
exp brain infarction/ or exp brain ischemia/ or exp intracranial aneurysm/ or exp occlusive
cerebrovascular disease/
2. stroke patient/
3. (stroke or poststroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$
or emboli$)).tw.
5. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or subarachnoid) adj5 (haemorrhage$ or
hemorrhage$ or haematoma$ or hematoma$ or bleed$)).tw.
6. 1 or 2 or 3 or 4 or 5
7. thromboembolism/ or thrombosis/ or leg thrombosis/ or vein thrombosis/ or deep vein thrombosis/ or
leg thrombophlebitis/ or thrombophlebitis/ or venous thromboembolism/
8. thrombosis prevention/ or postoperative thrombosis/
9. deep venous thrombo$.tw.
10. deep vein thrombo$.tw.
11. ((venous or vein) adj5 thrombo$).tw.
12. (DVT or VTE).tw.
13. thromboprophylaxis.tw.
14. phlebothrombosis.tw.
15. lung embolism/
16. lung artery/ or pulmonary artery/
17. embolism/ or artery embolism/ or embolism prevention/
18. 16 and 17
19. ((pulmonary or lung) adj5 (embol$ or thrombo$ or infarct$)).tw.
20. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 18 or 19
21. intermittent pneumatic compression device/
22. compression/ or compression therapy/ or leg compression/ or pneumatic tool/
23. clothing/ or protective clothing/ or cuff/ or elastic stockings/
24. (pneumatic adj5 (compression or device$ or appliance$ or stocking$ or hose or boot$ or suit
or suits)).tw.
25. ((pneumatic or electric$ or compression) adj5 pump$).tw.
26. (intermittent adj5 (compression or impulse device$)).tw.
27. (compression adj5 (device$ or system$ or stocking$ or hose or boot$)).tw.
28. ((elastic or antiembolic or anti-embolic) adj5 (stocking$ or hose)).tw.
29. (mechanical adj5 (prophylaxis or compression)).tw.
30. (inflatable adj5 (device$ or garment$ or stocking$ or hose or boot$)).tw.
31. IPC.tw.
32. electrostimulation/ or electrostimulation therapy/
33. (electric$ adj10 stimulat$).tw.
34. electrostimulation.tw.
35. or/21-34
36. 6 and 20 and 35
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Cumulative Index to Nursing and Allied Health Literature
(via EBSCOhost)
We used the following search strategy to search CINAHL (via EBSCOhost):
S52 .S9 and S23 and S51
S51 .S24 or S27 or S30 or S33 or S36 or S39 or S42 or S45 or S46 or S47 or S48 or S49 or S50
S50 .TI electrostimulation or AB electrostimulation
S49 .TI (electric* N10 stimulat*) or AB (electric* N10 stimulat*)
S48 .MH “electrical stimulation" or MH “electrotherapy"
S47 .TI (sequential N5 compression) or AB (sequential N5 compression)
S46 .TI IPC or AB IPC
S45 .S43 and S44
S44 .TI (device* or garment* or stocking* or hose or boot*) or AB (device* or garment* or stocking* or
hose or boot*)
S43 .TI inflatable or AB inflatable
S42 .S40 and S41
S41 .TI (prophylaxis or compression) or AB (prophylaxis or compression)
S40 .TI mechanical or AB mechanical
S39 .S37 and S38
S38 .TI (stocking* or hose) or AB (stocking* or hose)
S37 .TI (elastic or antiembolic or anti-embolic) or AB (elastic or antiembolic or anti-embolic)
S36 .S34 and S35
S35 .TI (device* or system* or stocking* or hose or boot*) or AB (device* or system* or stocking* or hose
or boot*)
S34 .TI compression or AB compression
S33 .S31 and S32
S32 .TI (compression or impulse device*) or AB (compression or impulse device*)
S31 .TI intermittent* or AB intermittent*
S30 .S28 and S29
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S29 .TI pump* or AB pump*
S28 .TI (pneumatic or electric* or compression)or AB (pneumatic or electric* or compression)
S27 .S25 and S26
S26 .TI (compression or device* or appliance* or stocking* or hose or boot* or suit or suits) or AB
(compression or device* or appliance* or stocking* or hose or boot* or suit or suits)
S25 .TI pneumatic or AB pneumatic
S24 .(MH “Compression Garments”) or (MH “Compression Therapy”)
S23 .S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S22
S22 .S20 and S21
S21 .TI (embol* or thrombo* or infarct*) or AB (embol* or thrombo* or infarct*)
S20 .TI (pulmonary or lung) or AB (pulmonary or lung)
S19 .MH “pulmonary artery” and MH “embolism”
S18 .MH “pulmonary embolism”
S17 .TI phlebothrombosis or AB phlebothrombosis
S16 .TI thromboprophylaxis or AB thromboprophylaxis
S15 .TI (DVT OR VTE) or AB (DVT OR VTE)
S14 .TI (vein N5 thrombo*) or AB (vein N5 thrombo*)
S13 .TI (venous N5 thrombo*) or AB (venous N5 thrombo*)
S12 .TI deep vein thrombo* or AB deep vein thrombo*
S11 .TI deep venous thrombo* or AB deep venous thrombo*
S10 .(MH “Thrombosis”) or (MH “thromboembolism”) or (MH “venous thrombosis”) or
(MH “thrombophlebitis”)
S9 .S1 or S2 or S5 or S8
S8 .S6 and S7
S7 .TI ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) or AB ( haemorrhage*
or hemorrhage* or haematoma* or hematoma* or bleed*)
S6 .TI ( brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid ) or AB ( brain* or
cerebr* or cerebell* or intracerebral or intracranial or subarachnoid)
S5 .S3 and S4
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S4 .TI ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus* ) or AB ( ischemi* or
ischaemi* or infarct* or thrombo* or emboli* or occlus*)
S3 .TI ( brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell*
or intracran* or intracerebral)
S2 .TI ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex
or SAH ) or AB ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva
or apoplex or SAH)
S1 .(MH “Cerebrovascular Disorders+”) or (MH “stroke patients”) or (MH “stroke units”)
British Nursing Index (via Ovid)
We used the following search strategy to search the British Nursing Index (via Ovid):
1. “equipment and supplies”/ and dressings/
2. (pneumatic adj5 (compression or device$ or appliance$ or stocking$ or hose or boot$ or suit
or suits)).tw.
3. ((pneumatic or electric$ or compression) adj5 pump$).tw.
4. (intermittent adj5 (compression or impulse device$)).tw.
5. (compression adj5 (device$ or system$ or stocking$ or hose or boot$)).tw.
6. ((elastic or antiembolic or anti-embolic) adj5 (stocking$ or hose)).tw.
7. (mechanical adj5 (prophylaxis or compression)).tw.
8. (inflatable adj5 (device$ or garment$ or stocking$ or hose or boot$)).tw.
9. ipc.tw.
10. (sequential adj5 compression).tw.
11. ((electric$ adj10 stimulat$) or electrostimulation).tw.
12. or/1-11
13. thrombosis/
14. deep venous thrombo$.tw.
15. deep vein thrombo$.tw.
16. ((venous or vein) adj5 thrombo$).tw.
17. (DVT or VTE).tw.
18. thromboprophylaxis.tw.
19. phlebothrombosis.tw.
20. ((pulmonary or lung) adj5 (embol$ or thrombo$ or infarct$)).tw.
21. or/13-20
22. stroke services/ or stroke/ or stroke rehabilitation/
23. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or
apoplex$ or SAH).tw.
24. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$
or emboli$ or occlus$)).tw.
25. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$
or hemorrhage$ or haematoma$ or hematoma$ or bleed$)).tw.
26. or/22-25
27. 12 and 21 and 26
DOI: 10.3310/hta19760 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 76
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Dennis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89


Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
